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Groote Schuur Hospital 
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Dear Professor Blockman 
We wish to request permission from the Research Ethics Committee to perform a 
retrospective observational study of all patients who presented with hepatitis at GF Jooste 
hospital during 2009. This study will aim to describe the numbers of patients seen with 
hepatitis, the spectrum of causes of hepatitis, outcome, and the current burden on the 
health care system. 
We will review case notes and laboratory records of all patients who were seen at GF 
Jooste during 2009 with an ALT of more than 200 and or total billirubin of more than 50. 
We will ascribe the most likely cause for hepatitis in each case, look at the relation of 
hepatitis to TB medication and ART, the duration of hospital stay and outcome. 
The focus will be to find out how many HIV and TB co infected patients present with drug 
induced hepatitis due to TB medication and ART. Our current clinical impression is that this 
is a frequent treatment complication in our setting and is associated with long hospital 
stays and lengthy drug rechallenges. However, this has not been formally described in our 
setting. With this study we will build a data base from which we can plan a future 
prospective study to look more in depth at causes of drug induced hepatitis, management 
thereof and the role of liver biopsy in this setting.  
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PART	  A:	  Protocol	  
	  
Burden	  of	  antituberculosis	  and	  antiretroviral	  drug-­induced	  liver	  injury	  at	  a	  




1.	  To	  determine	  the	  proportion	  of	  patients	  who	  present	  with	  TB	  treatment	  and	  
or	  ART-­‐associated	  drug-­‐induced	  liver	  injury	  (DILI)	  amongst	  all	  patients	  
presenting	  with	  significant	  liver	  injury	  to	  GF	  Jooste	  Hospital	  during	  the	  study	  
period.	  
2.	  To	  describe	  baseline	  clinical	  characteristics	  and	  management	  of	  TB	  treatment	  
and	  or	  ART-­‐associated	  DILI	  patients.	  
3.	  To	  describe	  the	  in-­‐patient	  and	  3-­‐month	  mortality	  of	  TB	  treatment	  and	  or	  ART-­‐
associated	  DILI	  patients.	  
	  
Background	  and	  Rationale:	  
	  	  
GF	  Jooste	  Hospital	  is	  a	  public	  sector	  referral	  hospital	  and	  serves	  a	  densely	  
populated	  area	  with	  a	  high	  burden	  of	  HIV	  and	  tuberculosis	  (TB).	  	  ART	  rollout	  in	  
the	  Western	  Cape	  started	  in	  2001/2002	  at	  two	  pilot	  clinics	  and	  is	  now	  well	  
established	  (1).	  Many	  patients	  are	  on	  concomitant	  TB	  treatment	  and	  ART.	  At	  
ART	  clinics	  in	  the	  referral	  area	  25-­‐40%	  of	  patients	  are	  on	  TB	  treatment	  when	  
they	  start	  ART	  (2,	  3).	  	  
At	  GF	  Jooste	  hospital	  many	  HIV	  positive	  patients	  are	  seen	  who	  are	  on	  TB	  
treatment	  and	  or	  ART,	  and	  present	  with	  symptomatic	  liver	  dysfunction.	  Patients	  
are	  on	  multiple	  hepatotoxic	  drugs,	  may	  have	  multiple	  opportunistic	  infections,	  
systemic	  sepsis	  and	  hepatic	  TB	  immune	  reconstitution	  disease	  also	  plays	  a	  role.	  
Anecdotally,	  these	  patients	  are	  complex	  to	  manage,	  require	  frequent	  specialist	  
input,	  spend	  a	  long	  time	  in	  ho pital	  and	  have	  high	  mortality.	  Management	  
guidelines	  are	  based	  on	  expert	  opinion	  and	  is	  not	  evidence	  based.	  In	  practice	  
management	  relies	  heavily	  on	  the	  attending	  clinicians’	  experience	  and	  clinical	  
judgment	  and	  management	  often	  differ	  widely	  between	  clinicians.	  	  
Mortality	  could	  be	  due	  to	  progression	  of	  TB	  and	  or	  HIV	  because	  of	  interruption	  
of	  effective	  therapy,	  other	  opportunistic	  infections	  or	  hospital	  acquired	  
infections.	  	  Few	  early	  liver	  biopsies	  are	  done	  and	  it	  is	  not	  known	  if	  early	  liver	  
biopsies	  would	  aid	  by	  guiding	  management	  of	  these	  patients.	  Prospective	  studies	  
are	  urgently	  needed	  to	  guide	  management	  in	  these	  patients.	  	  
The	  burden	  of	  TB	  treatment	  and	  or	  ART-­‐associated	  drug	  induced	  liver	  injury	  in	  
this	  setting	  has	  not	  been	  described	  to	  our	  knowledge,	  neither	  has	  management,	  
outcome	  or	  mortality.	  This	  study	  was	  performed	  to	  aid	  planning	  of	  prospective	  




GF	  Jooste	  Hospital	  is	  a	  public	  sector	  referral	  hospital,	  which	  serves	  a	  largely	  
socio-­‐economically	  disadvantaged	  population	  of	  1.2	  million	  people.	  In	  
Khayelitsha,	  which	  is	  the	  largest	  of	  the	  areas	  referring	  to	  GF	  Jooste	  Hospital,	  the	  










33%	  (4).	  Patients	  from	  surrounding	  ART	  and	  TB	  clinics	  who	  present	  with	  
symptomatic	  liver	  dysfunction	  are	  referred	  to	  GF	  Jooste	  Hospital	  where	  liver	  
function	  tests	  are	  performed.	  Based	  on	  the	  results	  of	  the	  liver	  function	  tests	  and	  
clinical	  condition,	  patients	  are	  either	  admitted,	  or	  managed	  as	  outpatients.	  GF	  
Jooste	  Hospital	  has	  an	  Infectious	  Diseases	  Referral	  Unit	  at	  which	  some	  patients	  








Results	  of	  all	  liver	  function	  tests	  (LFT)	  performed	  at	  the	  GF	  Jooste	  Hospital	  	  
National	  Health	  Laboratory	  Service	  laboratory	  from	  1	  January	  to	  30	  June	  2009	  
were	  reviewed.	  Records	  for	  all	  patients	  who	  met	  criteria	  for	  significant	  liver	  
dysfunction	  (see	  case	  definition	  below)	  were	  reviewed	  and	  data	  was	  extracted	  
with	  a	  data	  extraction	  sheet	  developed	  for	  the	  study	  (see	  appendix	  A	  &	  B).	  
	  
The	  following	  information	  was	  added	  to	  the	  protocol	  after	  protocol	  approval	  in	  
response	  to	  a	  request	  from	  an	  external	  reviewer:	  
The	  liver	  function	  tests	  were	  retrieved	  with	  a	  search	  function	  from	  the	  NHLS	  
database.	  This	  produced	  a	  list	  of	  all	  liver	  function	  tests	  performed	  at	  GF	  Jooste	  
hospital	  for	  a	  specific	  time	  period.	  The	  researcher	  sorted	  through	  this	  list	  
manually	  to	  identify	  all	  values	  that	  met	  study	  criteria	  and	  to	  eliminate	  duplicates.	  




1.	  Presence	  of	  significant	  liver	  dysfunction	  on	  GF	  Jooste	  laboratory	  records	  (refer	  
to	  case	  definition	  below).	  
2.	  Patient	  seen	  and	  managed	  at	  GF	  Jooste	  Hospital	  from	  1	  January	  2009	  –	  30	  June	  




Significant	  liver	  dysfunction	  
Liver	  dysfunction	  was	  defined	  as	  significant	  hepatocellular	  or	  cholestatic	  liver	  
injury.	  Significant	  was	  defined	  as	  resulting	  in	  Grade	  3	  or	  4	  elevation	  of	  alanine	  
amino	  transferase	  (ALT)	  and	  or	  total	  billirubin	  (TBR).	  The	  values	  are	  ALT≥200	  
U/l	  	  (>5	  times	  the	  upper	  limit	  of	  normal	  and	  indicative	  of	  hepatocellular	  injury),	  
and	  TBR≥44	  μmol/l	  (>2.5	  times	  the	  upper	  limit	  of	  normal	  and	  indicative	  of	  
cholestatic	  injury)	  (5).	  The	  Division	  of	  AIDS	  table	  for	  grading	  he	  severity	  of	  Adult	  
and	  Pediatric	  Adverse	  Events	  was	  used	  to	  determine	  these	  cut-­‐off	  points,	  see	  
appendix	  C	  &	  D.	  Patients	  who	  fulfilled	  one	  or	  both	  criteria	  were	  included.	  The	  
rationale	  for	  the	  case	  definition	  was	  that	  drug-­‐induced	  liver	  injury	  may	  present	  
with	  either	  hepatocellular	  or	  cholestatic	  liver	  function	  test	  results	  and	  at	  GF	  










tests	  on	  patients	  to	  save	  laboratory	  costs.	  In	  practice	  an	  ALT	  is	  done	  to	  screen	  for	  
hepatocellular	  injury	  and	  total	  billirubin	  to	  screen	  for	  cholestatic	  injury.	  	  
	  
TB	  treatment	  or	  ART-­associated	  liver	  dysfunction	  
Patient	  was	  managed	  as	  TB	  treatment	  and	  or	  ART-­‐associated	  drug	  induced	  liver	  
injury	  (DILI)	  by	  the	  admitting	  team,	  evident	  by	  changing	  or	  stopping	  TB	  
treatment	  and	  or	  ART	  during	  the	  hospital	  stay.	  
	  	  
	  
Other	  causes	  of	  liver	  dysfunction	  
A	  cause	  other	  than	  TB	  treatment	  and	  or	  ART-­‐associated	  DILI	  is	  identified	  as	  the	  
primary	  cause	  of	  liver	  injury	  and	  the	  admitting	  team’s	  treatment	  and	  
management	  is	  aimed	  at	  this	  cause.	  Thus,	  patients	  receiving	  TB	  treatment	  and	  or	  
ART	  who	  are	  admitted	  with	  another	  probable	  cause	  of	  liver	  injury	  and	  whose	  TB	  
treatment	  and	  or	  ART	  is	  continued	  unaltered,	  are	  included	  in	  this	  category.	  	  
	  
Sepsis	  
Sepsis	  was	  documented	  when	  the	  clinical	  presentation	  was	  compatible	  with	  
sepsis	  and	  the	  admitting	  team	  managed	  infection	  as	  the	  primary	  cause	  of	  illness.	  	  
	  
Hepatic	  Encephalopathy	  
The	  admitting	  team	  documented	  hepatic	  encephalopathy	  or	  signs	  and	  symptoms	  
compatible	  with	  encephalopathy.	  	  
	  
Determination	  of	  Outcome:	  
	  
Clinical	  management	  and	  outcome	  data	  were	  ascertained	  by	  review	  of	  patient	  
records.	  In-­‐hospital	  and	  3-­‐month	  (within	  90	  days	  of	  presentation)	  mortality	  
were	  recorded	  for	  TB	  treatment	  and	  or	  ART-­‐associated	  DILI	  patients,	  including	  
the	  cause	  of	  death	  where	  possible.	  Only	  in-­‐hospital	  mortality	  was	  recorded	  for	  
patients	  with	  liver	  injury	  due	  to	  other	  causes.	  Three-­‐month	  retention	  in	  care	  was	  
also	  recorded	  for	  the	  TB	  treatment	  and	  or	  ART	  associated	  DILI	  group.	  In	  the	  case	  
of	  TB	  treatment	  and	  or	  ART-­‐associated	  DILI,	  the	  Clinicom	  and	  eKapa	  electronic	  
databases	  were	  consulted	  to	  ascertain	  follow-­‐up	  and	  mortality	  documented	  
elsewhere	  in	  the	  Western	  Cape.	  Loss	  to	  follow-­‐up	  was	  defined	  as	  inability	  to	  




Frequency	  statistics	  and	  survival	  analysis	  will	  be	  performed	  with	  STATA	  11.1	  
software	  (2009).	  	  
	  
Appendices:	  (Following	  the	  protocol):	  
	  
• Data	  capture	  sheet	  for:	  GFJ	  Hepatitis	  Study:	  Initial	  Episode	  of	  
Hepatitis/Cholestasis	  











• Division	  of	  AIDS	  Table	  for	  Grading	  the	  severity	  of	  Adult	  and	  Pediatric	  
Adverse	  Events.	  Publish	  Date:	  December,	  2004	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• Date of presentation with hepatitis ____________ 
• Was patient admitted? Yes/No 
• Date of discharge/death/transfer/abscondment _____________ 
 
2. HIV status at presentation? Positive/Negative/Not tested 
• Most recent CD4 count  _________Date of CD4 ____________ 
 
3. On ART at presentation?  Yes/No/Unknown 
• Date started ___________ 










If other, name medication ___________________________________ 
 ________________________________________________________ 
 
4. On TB treatment at presentation?  Yes/No/Unknown 
• Date started ____________ 
Regimen at presentation: 
Rif/INH/EMB/PZA  






If other TB medication, name medication ______________________ 
 
5. Cotrimoxazole  Yes/No/Unknown 
• Primary prophylaxis? Yes/No 
• Secondary prophylaxis? Yes/No 




GSH/Carnation/KDH folder needed  
Busy with 3 month f/up  
TB or ART DILI  
Other  
Name________________________________________________ 
GFJ Folder number_____________________________________ 
DOB_____________ 
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6. List all additional medication on presentation ____________________ 
________________________________________________________
________________________________________________________
   





8. If TB treatment or ART NOT the cause of hepatitis, what is the most 




TB IRIS  
Viral hepatitis (A,B,C)  
Sepsis  
Toxins  
Disseminated tuberculosis  
Other medication  
Other cause  
Unknown  
Name other cause  ________________________________________ 











Died during initial admission  
Discharged  
Referred to another hospital  
Absconded   
Date of last record of patient ________________ 
Cause of death ___________________________ 
 
IF QUESTION 8 ANSWERED, STOP QUESTIONAIRE HERE 
 
9. LFT values: 
  Presentation Peak (this 
episode) 
AST   
ALT   
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ALP   
TBR   
INR   
• Hepatic encephalopathy at presentation? Yes/No 
 
• If INR >1.4, is there any reason for abnormal INR apart from 
liver dysfunction? (eg CCF/Warfarin/DIC) Yes/No 
Reason______________________________________ 
   
10. Hepatitis studies 
• Hep B sAg   
• Hep B eAg   
• Hep C Ab 
 
11. Outcome 
Died acutely (during initial admission)  
Died during follow up (3m)  
Discharged and known to be alive and in care (3 m)  
Discharged, seen as outpatient, LTFU (3 m)  
Discharged with no information after discharge  
Absconded  
• Cause of death ____________________________ 
• Date of last record of patient __________________ 
   
12. Management 
TB treatment: 
• Was treatment stopped completely?  Yes/No 
• Date stopped ___________ 
• Changed to liver safer medication?  Yes/No 
• Date started ____________ 





Stopped? Rechallenged or 
started? 
Tolerated? 
Rif Yes No Yes No Yes No Yes No 
INH Yes No Yes No Yes No Yes No 
EMB Yes No Yes No Yes No Yes No 
PZA Yes No Yes No Yes No Yes No 
Strep Yes No Yes No Yes No Yes No 
MDR  Yes No Yes No Yes No Yes No 
Bactrim Yes No Yes No Yes No Yes No 
  






Pos Neg N/D 
Pos Neg N/D 














Completely stopped?  
NVP changed to EFV?  
NVP interrupted and EFV restarted later?  
EFV changed to Lop/Rit?  
EFV interrupted and restarted on EFV later?  
EFV interrupted and started on Lop/Rit later?  
Other  
Details of other _________________________________ 
______________________________________________ 
 
13. Time taken to get back onto optimal therapy  
• TB treatment (Rif based)  Date _ ________ 
• ART (Tripple therapy/PI based)  Date _________ 




   
ART___________________________________________ 
  _______________________________________________ 
 
• Loss to follow up during rechallenge?  Yes/No 
 
14. Additional relevant investigations Yes/No 
Liverbiopsy Conclusion  
 
ERCP Conclusion  
 
USS abdomen Conclusion  
 
CT abdomen Conclusion  
 
 
15. Outpatient follow up related to hepatitis ( within 3 months after initial 
presentation)  Yes/No 
Number of visits ______ 
 
16. Possible contributing factors to hepatitis? (differential diagnosis eg TB 






17. Did patient have a subsequent episode of abnormal LFT’s investigated 
at hospital?  Yes/ No 












GF Jooste Hepatitis Study  




 Date of presentation with hepatitis ____________ 
Was patient admitted?  Yes/No 
Date of discharge/death _____________ 
 
2. Likely primary cause of hepatitis 
• ________________________ 




3. Drug interruptions/changes? 












4. Additional investigations done? Yes/No 
Investigation Conclusion 
USS abdomen  
CT abdomen  





GSH/Carnation/KDH folder needed  
Busy with 3 month f/up  
TB or ART DILI  
Other  
Name________________________________________________ 
GFJ Folder number_____________________________________ 
DOB_____________ 














5. Followed up as outpatient? Yes/No 
Number of visits (3 months after this episode) ___________ 
 
6. Outcome 
Died during initial admission  
Discharged  
Referred to another hospital  
Absconded   
• Date of last record of patient ________________ 
• Cause of death___________________________ 
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diagnostic finding AND 
intervention indicated 
New onset Wit 
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Worsening symptomatic 
congestive heart failure 
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Part	  B:	  Structured	  literature	  review	  
Objectives	  
The	  objective	  of	  this	  literature	  review	  is	  to	  summarize	  key	  concepts	  related	  to	  
tuberculosis	  (TB)	  treatment	  and	  or	  antiretroviral	  therapy	  (ART)-­‐associated	  
drug-­‐induced	  liver	  injury	  (DILI)	  from	  currently	  published	  literature	  with	  the	  
focus	  on	  HIV	  as	  a	  risk	  factor	  for	  TB	  DILI	  and	  concomitant	  ART	  and	  TB	  treatment	  
as	  a	  risk	  factor	  for	  DILI.	  This	  review	  serves	  as	  an	  introduction	  to	  the	  research	  
study	  that	  follows.	  	  The	  study	  was	  conducted	  at	  GF	  Jooste	  Hospital	  and	  assessed	  
the	  burden	  of	  TB	  treatment	  and	  or	  ART-­‐associated	  DILI	  at	  a	  referral	  hospital	  in	  
South	  Africa.	  	  
Search	  Methods	  &	  Selection	  Criteria:	  
A	  Pubmed	  search	  was	  performed	  with	  key	  words	  and	  combinations	  of	  HIV,	  
tuberculosis,	  hepatotoxicity	  and	  drug	  induced	  liver	  injury.	  All	  studies	  that	  
reported	  hepatotoxicity	  and	  included	  1)	  adult	  HIV	  positive	  patients	  on	  
antiretroviral	  therapy	  and	  or;	  2)	  adult	  patients	  on	  TB	  treatment	  and	  or;	  3)	  adult	  
patients	  on	  concomitant	  TB	  treatment	  and	  antiretroviral	  therapy,	  were	  
reviewed.	  Studies	  including	  paediatric	  patients,	  studies	  concerning	  TB	  
preventative	  therapy	  and	  studies	  in	  TB	  patients	  which	  did	  not	  include	  any	  HIV-­‐
infected	  patients	  were	  not	  assessed	  for	  this	  review.	  References	  of	  relevant	  
studies	  were	  also	  examined	  and	  used	  to	  find	  additional	  articles	  for	  this	  review.	  
















Burden	  of	  tuberculosis	  and	  HIV:	  
An	  estimated	  34	  million	  people	  are	  HIV-­‐infected	  globally	  (1).	  There	  were	  an	  
estimated	  8.8	  million	  incident	  TB	  cases	  worldwide	  in	  2010,	  of	  which	  an	  
estimated	  1.3	  million	  cases	  occurred	  in	  people	  who	  were	  HIV-­‐infected	  (2).	  In	  
South	  Africa	  TB	  case	  notifications	  reached	  almost	  400	  000	  per	  annum	  in	  2010,	  
with	  61%	  of	  incident	  TB	  cases	  being	  HIV	  co-­‐infected	  (2).	  In	  the	  Western	  Cape	  
province	  TB	  prevalence	  at	  ART	  initiation	  is	  very	  high.	  Two	  large	  public	  sector	  
antiretroviral	  (ART)	  clinics	  in	  Cape	  Town	  reported	  concomitant	  TB	  treatment	  in	  
25%	  and	  40%	  of	  patients	  respectively,	  at	  time	  of	  ART	  initiation	  (3,	  4).	  Forty-­‐two	  
percent	  of	  HIV-­‐positive	  incident	  TB	  cases	  in	  South	  Africa	  received	  both	  ART	  and	  
TB	  treatment	  in	  2009,	  compared	  with	  18%	  in	  2008	  (5)	  .	  	  	  
The	  importance	  of	  drug	  induced	  liver	  injury	  (DILI):	  
Multi-­‐drug	  treatment	  for	  active	  TB	  has	  several	  well-­‐known	  side	  effects.	  One	  of	  
the	  most	  common	  and	  serious	  is	  hepatotoxicity	  (6).	  All	  classes	  of	  ART	  are	  
potentially	  hepatotoxic	  (7).	  These	  overlapping	  toxicity	  profiles	  in	  often	  
overlapping,	  multi-­‐drug	  treatment	  regimens,	  cause	  complex	  clinical	  scenarios	  in	  
patients	  who	  present	  with	  liver	  injury.	  Commonly	  used	  prophylactic	  medication	  
like	  cotrimoxazole,	  fluconazole	  and	  other	  conditions	  like	  tuberculosis-­‐associated	  
immune	  reconstitution	  inflammatory	  syndrome	  (TB	  IRIS)	  and	  systemic	  sepsis	  
may	  also	  contribute	  to	  liver	  dysfunction	  (8-­‐10).	  	  
Clinical	  presentation	  and	  diagnosis	  of	  DILI:	  
Clinical	  presentation	  of	  DILI	  is	  non-­‐specific	  and	  initially	  indistinguishable	  from	  
liver	  injury	  due	  to	  other	  causes,	  like	  viral	  hepatitis	  (11,	  12).	  	  DILI	  should	  always	  











HIV	  infection	  and/or	  tuberculosis.	  There	  is	  no	  diagnostic	  test	  to	  distinguish	  DILI	  
from	  other	  causes	  of	  liver	  dysfunction.	  Careful	  history	  taking	  (with	  focus	  on	  
timing	  of	  initiation	  of	  all	  treatment	  regimens,	  including	  herbal	  medication	  and	  
timing	  of	  symptom	  onset	  in	  relation	  to	  medication),	  physical	  examination	  and	  
focused	  clinical	  investigations	  should	  rule	  out	  other	  causes	  of	  liver	  injury	  before	  
making	  the	  diagnosis	  of	  DILI	  (13,	  14).	  	  
Mechanisms	  of	  DILI:	  
Mechanisms	  of	  DILI	  are	  complex	  and	  poorly	  understood.	  It	  is	  likely	  that	  each	  
drug	  has	  a	  unique	  mechanism	  of	  causing	  toxicity,	  which	  determines	  clinical	  
presentation.	  Several	  drug	  targets	  have	  been	  identified	  and	  the	  pattern	  of	  cell	  
injury	  depends	  on	  which	  target	  is	  affected	  by	  a	  specific	  drug.	  Each	  target	  triggers	  
a	  different	  mechanism	  and	  thus	  a	  different	  pattern	  of	  hepatocyte	  injury.	  
Manifestations	  of	  DILI	  in	  individuals	  are	  further	  influenced	  by	  demographic	  
factors,	  genetic	  susceptibility	  and	  environmental	  factors	  (11,	  13,	  15,	  16).	  First-­‐
line	  treatment	  for	  active	  TB	  in	  South	  Africa,	  includes	  rifampicin,	  isoniazid,	  
ethambutol	  and	  pyrazinamide	  (17).	  Rifampicin,	  isoniazid	  and	  pyrazinamide	  are	  
known	  hepatotoxic	  drugs.	  Isoniazid	  is	  thought	  to	  cause	  DILI	  through	  its	  toxic	  
metabolites,	  acetylhydrazine	  or	  hydrazine	  (18).	  It	  is	  not	  well	  understood	  how	  
rifampicin	  and	  pyrazinamide	  cause	  DILI	  (12).	  Antiretroviral	  treatment	  in	  South	  
Africa	  includes	  nucleoside	  (or	  nucleotide)	  reverse	  transcriptase	  inhibitors	  
(NRTI),	  non-­‐nucleoside	  reverse	  transcriptase	  inhibitors	  (NNRTI)	  and	  protease	  
inhibitors	  (PI).	  NNRTI	  drugs	  (efavirenz	  and	  nevirapine)	  most	  commonly	  cause	  
an	  allergic	  hepatitis,	  which	  is	  associated	  with	  rash	  and	  systemic	  symptoms	  (19).	  	  
NRTI	  drugs	  (stavudine,	  didanosine,	  zidovudine	  and	  tenofovir),	  may	  cause	  











(20).	  This	  usually	  results	  in	  moderate	  elevations	  of	  	  liver	  enzymes.	  Importantly	  it	  
has	  also	  been	  shown	  that	  ART	  naïve	  HIV-­‐infected	  patients	  have	  underlying	  
mitochondrial	  damage	  on	  liver	  biopsy	  (21):	  this	  may	  predispose	  to	  NRTI	  
damage.	  It	  is	  unknown	  how	  PI’s	  cause	  DILI	  and	  occurrence	  of	  DILI	  varies	  with	  
specific	  PI	  used	  (7).	  Depending	  on	  the	  mechanism	  of	  DILI,	  there	  may	  be	  mainly	  
hepatocellular	  injury,	  cholestatic	  injury	  or	  a	  mixed	  pattern.	  This	  manifests	  as	  
either	  a	  rise	  in	  transaminases	  (alanine	  transaminase	  [ALT]	  and	  aspartate	  
aminotransferase	  [AST])	  in	  the	  case	  of	  hepatocellular	  injury,	  a	  rise	  in	  cholestatic	  
enzymes	  (gamma	  glutamyl-­‐transpeptidase	  [GGT],	  alkaline	  phosphatase	  [ALP]	  
and	  or/total	  bilirubin	  [TBR])	  in	  the	  case	  of	  cholestatic	  injury	  or	  rise	  in	  both	  
(mixed	  picture).	  	  
Management	  of	  DILI:	  
If	  liver	  injury	  is	  severe,	  treatment	  needs	  to	  be	  interrupted.	  Failure	  to	  interrupt	  
the	  offending	  drug	  may	  result	  in	  death	  (22).	  Treatment	  interruption	  for	  TB	  and	  
or	  HIV	  carries	  the	  risk	  of	  disease	  progression	  and	  death	  (6)	  and	  drug	  resistance.	  
Once	  liver	  enzymes	  have	  normalized,	  relevant	  treatment	  needs	  to	  be	  re-­‐
introduced,	  usually	  in	  a	  step-­‐wise	  manner.	  Details	  of	  management	  and	  drug	  re-­‐












Occurrence	  of	  TB	  treatment	  associated	  DILI	  (TB	  DILI)	  and	  HIV	  as	  a	  risk	  
factor	  for	  TB	  DILI:	  
a)	  Observational	  studies	  that	  included	  HIV-­infected	  and	  HIV-­uninfected	  
patients	  (but	  HIV	  testing	  was	  not	  routinely	  done)	  and	  reported	  
tuberculosis	  treatment-­associated	  drug-­induced	  liver	  injury	  (TB	  DILI):	  
(summarized	  in	  table	  1)	  
Schaberg	  et	  al	  retrospectively	  reviewed	  a	  cohort	  of	  519	  hospitalized	  TB	  patients	  
in	  Germany.	  200	  patients	  were	  tested	  for	  HIV	  and	  9	  were	  HIV	  positive.	  Patient	  
records	  were	  reviewed	  for	  adverse	  events	  severe	  enough	  to	  interrupt	  TB	  
treatment	  and	  55	  (11%)	  cases	  of	  hepatotoxicity	  meeting	  this	  criterion	  occurred.	  
HIV	  infection	  was	  not	  found	  to	  be	  a	  risk	  factor	  for	  development	  of	  severe	  adverse	  
events,	  but	  the	  number	  of	  HIV-­‐infected	  patients	  in	  this	  cohort	  was	  small	  (23).	  	  
A	  study	  by	  Yee	  et	  al	  in	  Canada	  reported	  on	  all	  serious	  side	  effects	  of	  first	  line	  
tuberculosis	  treatment,	  which	  resulted	  in	  the	  treatment	  being	  stopped	  or	  
adjusted,	  and	  amongst	  these	  was	  hepatotoxicity.	  HIV	  infection	  had	  an	  adjusted	  
hazard	  ratio	  (aHR)	  of	  3.8	  (95%	  confidence	  interval	  [CI]	  1.05-­‐13.4)	  for	  the	  
development	  of	  serious	  adverse	  events	  on	  TB	  treatment.	  The	  hazard	  ratio	  of	  HIV	  
infection	  for	  the	  development	  of	  DILI,	  specifically,	  was	  not	  reported	  (24).	  	  
A	  study	  in	  Malaysia	  by	  Marzuki	  et	  al,	  report	  a	  9.7%	  prevalence	  of	  TB	  DILI	  in	  a	  
retrospective	  cohort	  of	  473	  TB	  patients.	  They	  selected	  all	  46	  cases	  of	  TB	  DILI	  and	  
then	  randomly	  selected	  138	  controls	  in	  a	  nested	  case	  control	  study.	  They	  
reported	  HIV	  infection	  as	  a	  significant	  independent	  risk	  factor	  for	  developing	  TB	  
DILI	  with	  an	  odds	  ratio	  of	  3.54	  (95%	  CI	  =	  1.25-­‐10.05).	  There	  were	  9	  (20%)	  HIV-­‐











De	  Castro	  et	  al	  reported	  30	  cases	  of	  DILI	  in	  a	  prospective	  cohort	  of	  154	  TB	  
patients	  in	  Brazil.	  19	  cases	  of	  DILI	  occurred	  amongst	  60	  HIV-­‐infected	  persons	  
and	  11	  amongst	  94	  HIV	  uninfected	  persons.	  In	  this	  study	  HIV	  infection	  was	  an	  
independent	  risk	  factor	  for	  the	  development	  of	  TB	  DILI	  with	  a	  risk	  ratio	  of	  2.72	  
(95%	  CI=1.39-­‐5.28)	  (26).	  	  	  
In	  an	  Iranian	  study	  by	  Baghaei	  et	  al,	  a	  TB	  DILI	  incidence	  of	  13%	  was	  reported	  in	  
a	  prospective	  cohort	  study	  of	  761	  patients.	  The	  definition	  used	  for	  diagnosis	  of	  
DILI	  was	  not	  clear.	  Few	  patients	  were	  tested	  for	  HIV	  infection.	  Amongst	  those	  
who	  were	  tested,	  DILI	  occurred	  in	  7/43	  (16%)	  HIV	  positive	  patients	  and	  in	  
54/196	  (28%)	  HIV	  negative	  patients.	  HIV	  was	  not	  reported	  as	  a	  risk	  factor	  for	  TB	  
DILI	  in	  this	  study	  (27).	  	  	  
Tostmann	  et	  al	  enrolled	  112	  TB	  patients	  prospectively	  in	  Tanzania	  and	  found	  no	  
cases	  of	  DILI.	  There	  was	  a	  low	  HIV	  co-­‐infection	  rate	  with	  11	  patients	  HIV	  co-­‐
infected,	  and	  none	  were	  taking	  ART	  at	  the	  start	  of	  the	  study.	  6	  participants	  
started	  efavirenz	  based	  ART	  during	  the	  course	  of	  the	  study.	  Patients	  were	  only	  
followed	  during	  the	  two-­‐month	  intensive	  phase	  of	  TB	  treatment	  (28).	  	  	  
In	  a	  prospective	  study	  reported	  by	  Lorent	  et	  al	  in	  Rwanda	  there	  were	  24	  (9.5%)	  
episodes	  of	  DILI	  amongst	  253	  tuberculosis	  cases.	  Twenty-­‐two	  (8.7%)	  of	  these	  
episodes	  occurred	  amongst	  HIV-­‐infected	  patients.	  Two	  thirds	  of	  the	  cohort	  (167)	  
people	  were	  HIV-­‐infected.	  A	  third	  of	  HIV-­‐infected	  patients	  were	  on	  ART	  at	  time	  
of	  initiation	  of	  TB	  treatment,	  a	  third	  started	  ART	  during	  intensive	  phase	  of	  TB	  
treatment	  and	  virtually	  all	  patients	  were	  on	  cotrimoxazole	  prophylaxis.	  HIV	  
infection	  was	  an	  independent	  predictor	  for	  serious	  adverse	  events	  during	  first	  
line	  tuberculosis	  treatment;	  in	  this	  cohort	  64	  (23%)	  patients	  developed	  serious	  











ratio	  for	  HIV	  as	  a	  predictor	  of	  serious	  adverse	  events	  was	  2.43	  (95%	  CI	  =	  1.35-­‐
8.67;	  p-­‐value	  =	  0.009)	  (29).	  
	  
	  
b)	  Studies	  that	  directly	  compared	  TB	  DILI	  in	  HIV-­infected	  and	  HIV	  
uninfected	  patients	  (HIV	  testing	  routinely	  done):	  (summarized	  in	  table	  2)	  
Perriens	  et	  al	  enrolled	  523	  TB	  patients	  prospectively	  in	  Zaire.	  335	  patients	  were	  
HIV	  co-­‐infected	  and	  this	  was	  prior	  to	  availability	  of	  ART.	  They	  do	  not	  mention	  
the	  definition	  of	  hepatitis,	  but	  state	  that	  no	  hepatitis	  was	  seen	  in	  the	  cohort,	  
although	  increased	  levels	  of	  ALT,	  AST	  and	  billirubin	  was	  sometimes	  seen.	  These	  
liver	  enzyme	  elevations	  were	  not	  significantly	  associated	  with	  HIV	  infection	  (30).	  	  
In	  a	  prospective	  cohort	  study	  conducted	  in	  Haiti	  in	  1990,	  Chaisson	  et	  al	  enrolled	  
427	  TB	  patients	  of	  which	  177	  were	  HIV-­‐infected.	  They	  found	  similar	  rates	  of	  DILI	  
in	  both	  groups:	  12%	  in	  the	  HIV-­‐infected	  TB	  patients	  and	  9%	  (not	  statistically	  
significant)	  in	  the	  uninfected	  group.	  This	  was	  prior	  to	  availability	  of	  ART	  (31).	  	  
A	  retrospective	  study	  by	  Breen	  et	  al	  in	  the	  United	  Kingdom	  compared	  the	  
occurrence	  of	  grade	  3	  and	  4	  adverse	  events	  (AE)	  during	  TB	  therapy	  between	  156	  
HIV-­‐TB	  co-­‐infected	  patients	  and	  156	  HIV	  negative	  TB	  patients	  treated	  at	  the	  
same	  facilities.	  	  They	  found	  an	  increased	  number	  of	  grade	  3	  and	  4	  adverse	  events	  
amongst	  TB-­‐HIV	  co-­‐infected	  patients,	  40%	  vs.	  26%	  (p=0.008).	  However,	  there	  
were	  20	  cases	  of	  DILI	  in	  each	  group	  and	  no	  excess	  treatment	  interruptions	  in	  the	  
HIV-­‐infected	  group.	  Seventeen	  co-­‐infected	  patients	  had	  treatment	  interrupted	  
due	  to	  DILI	  vs.	  20	  in	  the	  HIV	  negative	  group.	  Twenty-­‐nine	  HIV-­‐infected	  patients	  
were	  on	  ART	  at	  initiation	  of	  TB	  treatment	  and	  a	  further	  82	  started	  ART	  within	  a	  











ethnic	  group,	  the	  black	  African	  population	  showed	  a	  difference	  between	  the	  
groups,	  with	  more	  grade	  3	  and	  4	  AE’s	  and	  more	  TB	  treatment	  interruptions	  in	  
those	  HIV-­‐infected,	  43%	  vs.	  21%,	  and	  13%	  vs.	  6%,	  respectively.	  The	  numbers	  of	  
DILI	  cases	  in	  the	  black	  African	  group	  was	  not	  reported	  (32).	  	  
A	  prospective	  study	  in	  Ethiopia	  by	  Yimer	  at	  al	  enrolled	  197	  consecutive	  TB	  
patients.	  All	  patients	  were	  tested	  for	  HIV	  and	  103	  (52.3%)	  were	  HIV	  positive.	  34	  
cases	  of	  DILI	  occurred	  and	  26	  were	  in	  HIV-­‐infected	  persons.	  HIV	  was	  an	  
independent	  risk	  factor	  for	  developing	  TB	  DILI	  in	  multivariate	  analysis	  with	  an	  
adjusted	  odds	  ratio	  of	  3.6	  (95%	  CI=1.5-­‐8.5;	  p=0.002).	  There	  was	  no	  mention	  of	  
antiretroviral	  therapy	  in	  this	  paper	  despite	  80%	  of	  patients	  having	  a	  CD4	  cell	  
count	  of	  less	  than	  200	  cells/mm3	  (33).	  	  
A	  Brazilian	  case-­‐control	  study	  by	  Coca	  et	  al	  analysed	  a	  cohort	  of	  30	  HIV	  positive	  
TB	  patients	  and	  compared	  the	  occurrence	  of	  DILI	  with	  a	  control	  group	  of	  132	  
HIV	  negative	  TB	  patients.	  They	  assessed	  the	  presence	  of	  DILI	  by	  using	  three	  
different	  definitions	  of	  hepatotoxicity.	  The	  definitions	  were:	  a)	  ALT	  >	  three	  times	  
the	  lower	  limit	  of	  normal	  (LLN),	  b)	  ALT	  >	  three	  times	  the	  upper	  limit	  of	  normal	  
(ULN)	  and	  c)	  ALT	  >3	  t mes	  ULN	  plus	  total	  billirubin	  >2	  ULN.	  	  The	  first	  definition	  
is	  not	  clinically	  relevant.	  Hepatotoxicity,	  using	  definition	  b)	  occurred	  in	  6	  (20%)	  
HIV-­‐infected	  and	  12	  (9.1%)	  uninfected	  persons	  and	  using	  definition	  c)	  in	  6	  
(20%)	  HIV-­‐infected	  and	  11	  (8.3%)	  uninfected	  persons.	  There	  was	  no	  mention	  of	  
antiretroviral	  therapy	  or	  CD4	  counts	  in	  this	  paper.	  HIV	  was	  not	  a	  risk	  factor	  for	  














Identifying	  risk	  factors	  for	  DILI	  in	  HIV-­TB	  co-­infected	  patients:	  	  
Studies	  that	  included	  only	  HIV-­TB	  co-­infected	  patients:	  (summarized	  in	  
table	  3)	  
Dean	  et	  al	  retrospectively	  reviewed	  188	  HIV-­‐TB	  co-­‐infected	  patients	  treated	  at	  
HIV	  clinics	  in	  London	  from	  1996-­‐1999.	  15%	  of	  patients	  were	  on	  ART	  at	  start	  of	  
TB	  treatment	  and	  45%	  started	  ART	  during	  TB	  therapy	  at	  a	  median	  of	  2	  months.	  
Details	  of	  therapy	  were	  only	  available	  for	  99	  patients	  and	  of	  these	  11	  
experienced	  DILI.	  In	  multivariate	  analysis	  female	  gender	  (OR	  2.03;	  95%	  CI=1.09-­‐
3.77)	  and	  concomitant	  TB	  and	  HIV	  treatment	  (OR	  1.88;	  95%=1.03-­‐3.42)	  were	  
independently	  associated	  with	  the	  development	  of	  adverse	  events	  (35).	  	  
Tostmann	  et	  al	  reports	  on	  hepatotoxicity	  in	  a	  randomized	  controlled	  trial	  
initially	  reported	  by	  Boeree	  et	  al	  (36).	  The	  trial	  investigated	  cotrimoxazole	  
prophylaxis	  at	  different	  doses	  in	  newly	  diagnosed	  smear	  positive	  TB	  patients.	  All	  
patients	  were	  HIV-­‐infected,	  but	  none	  were	  taking	  ART.	  They	  report	  3	  cases	  of	  
grade	  3	  DILI	  and	  none	  with	  grade	  4	  DILI.	  25%	  of	  patients	  either	  died	  or	  were	  lost	  
to	  follow	  up	  during	  the	  trial	  and	  those	  who	  were	  lost	  to	  follow	  up	  were	  more	  
likely	  to	  have	  had	  a	  high	  ALT	  at	  inclusion.	  It	  is	  likely	  that	  the	  rate	  of	  DILI	  in	  this	  
trial	  was	  underestimated	  and	  DILI	  could	  have	  been	  due	  to	  TB	  medication	  or	  
cotrimoxazole	  prophylaxis	  (37).	  	  
Pukenyte	  et	  al	  performed	  a	  retrospective	  observational	  study	  in	  France	  to	  
determine	  the	  incidence	  and	  risk	  factors	  for	  severe	  liver	  toxicity	  in	  HIV-­‐TB	  co-­‐
infected	  patients.	  One	  hundred	  and	  forty	  four	  patients	  who	  were	  treated	  for	  TB	  
at	  6	  different	  hospitals	  over	  a	  12-­‐year	  period	  were	  included.	  	  The	  majority	  of	  
patients	  were	  not	  on	  ART.	  	  Of	  25	  patients	  who	  were	  on	  ART	  3	  developed	  DILI.	  	  











In	  multivariate	  analysis,	  independent	  risk	  factors	  for	  liver	  toxicity	  were	  
abnormal	  ALT	  at	  baseline	  with	  adjusted	  hazard	  ratio	  (aHR)	  =	  3.86	  (95%	  
CI=1.15–12.88;	  p=0.028),	  increased	  baseline	  billirubin	  levels	  with	  aHR	  =	  4.34	  
(95%	  CI=1.13–16.7;	  p=0.033),	  and	  the	  concomitant	  use	  of	  fluconazole	  with	  TB	  
treatment,	  aHR	  =	  4.90	  (95%	  CI=1.52–15.86;	  p=0.008)	  (38).	  
Moses	  et	  al	  performed	  a	  retrospective	  observational	  study	  in	  Malawi,	  which	  
included	  all	  new	  adult	  TB	  patients	  (n=	  156)	  registered	  in	  a	  rural	  hospital	  from	  
June	  –	  December	  2007.	  Patients	  were	  HIV-­‐infected;	  ART-­‐naive	  and	  received	  
nevirapine	  based	  ART	  during	  TB	  treatment.	  Malawi	  used	  a	  fixed	  dose	  
combination	  of	  stavudine,	  lamivudine	  and	  nevirapine	  as	  first	  line	  ART.	  	  Two	  
patients	  developed	  grade	  2	  hepatotoxicity	  and	  1	  developed	  grade	  3	  toxicity,	  
which	  was	  an	  incidence	  rate	  for	  grade	  2-­‐4	  hepatoxicity	  of	  4.2	  per	  10	  years	  of	  
follow	  up,	  95%	  CI=1.4-­‐13.1	  (39).	  	  
Mankhatitham	  et	  al	  analyzed	  the	  hepat toxicity	  data	  of	  the	  N2R	  trial	  conducted	  
by	  Manosuthi	  et	  al	  (40).	  The	  N2R	  trial	  was	  a	  randomized	  controlled	  trial	  in	  
Thailand	  which	  enrolled	  142	  HIV-­‐infected	  TB	  patients	  receiving	  rifampicin	  based	  
TB	  treatment	  during	  2006	  &	  2007.	  Patients	  were	  randomized	  to	  start	  either	  
nevirapine	  or	  efavirenz	  based	  ART.	  These	  patients	  	  had	  a	  high	  rate	  of	  chronic	  
viral	  hepatitis.	  Five	  percent	  had	  chronic	  hepatitis	  B	  and	  25%	  had	  chronic	  
hepatitis	  C	  infection	  at	  baseline.	  There	  were	  9	  episodes	  of	  grade	  3	  or	  4	  
transaminitis	  or	  hyperbilirubinaemia.	  Chronic	  hepatitis	  C	  at	  baseline	  was	  the	  
only	  independent	  predictor	  of	  hepatotoxicity	  in	  this	  study	  with	  an	  adjusted	  odds	  
ratio	  =	  3.03	  (95%	  CI=1.26-­‐7.29)	  (41).	  
Yimer	  et	  al	  studied	  a	  prospective	  cohort	  of	  Ethiopian	  patients	  enrolled	  from	  











started	  on	  efavirenz	  based	  ART	  within	  8	  weeks	  of	  starting	  TB	  treatment.	  Out	  of	  
373	  patients	  20	  developed	  severely	  elevated	  (more	  than	  5	  times	  the	  ULN)	  
transaminases	  (likely	  TB	  DILI)	  prior	  to	  starting	  ART	  and	  were	  excluded	  from	  the	  
analysis.	  The	  reason	  for	  this	  was	  that	  the	  investigators	  wanted	  to	  assess	  risk	  
factors	  for	  developing	  DILI	  on	  concomitant	  TB	  treatment	  and	  ART.	  There	  were	  
106	  cases	  of	  DILI	  on	  concomitant	  TB	  treatment	  and	  ART,	  of	  which	  65	  were	  
severe	  DILI	  with	  transaminases	  more	  than	  5	  times	  the	  ULN.	  They	  identified	  
female	  sex,	  low	  BMI,	  high	  efavirenz	  levels,	  high	  pre-­‐treatment	  ALT/AST,	  low	  
hemoglobin	  (Hb)	  and	  low	  albumin	  to	  be	  associated	  with	  development	  of	  DILI.	  It	  
is	  not	  clear	  whether	  this	  was	  on	  univariate	  or	  multivariate	  analysis.	  They	  also	  
performed	  a	  case	  control	  study	  analysing	  genetic	  variants	  with	  respect	  to	  drug	  
metabolising	  status	  and	  found	  slow	  acetylation	  status,	  CYP2B6*6/*6	  and	  
ABCB13435TT	  genotypes	  to	  be	  predictors	  of	  DILI	  in	  this	  population.	  It	  is	  not	  

















Concomitant	  TB	  treatment	  as	  a	  risk	  factor	  for	  DILI	  in	  patients	  on	  ART:	  
Comparing	  DILI	  in	  patients	  on	  ART	  alone	  vs.	  patients	  on	  ART	  and	  TB	  
treatment:	  (summarized	  in	  table	  4)	  
Hoffman	  et	  al	  retrospectively	  reviewed	  a	  cohort	  of	  868	  HIV-­‐infected	  patients	  in	  
South	  Africa	  in	  an	  occupational	  setting	  (mainly	  men),	  who	  accessed	  ART	  through	  
a	  work	  place	  programme.	  Twenty	  five	  percent	  of	  patients	  were	  on	  concomitant	  
TB	  treatment	  and	  17%	  of	  a	  randomly	  selected	  sub-­‐group	  were	  hepatitis	  B	  co-­‐
infected.	  They	  found	  concomitant	  TB	  treatment	  and	  chronic	  hepatitis	  B	  infection	  
to	  be	  independent	  predictors	  of	  grade	  3	  or	  4	  DILI	  with	  an	  adjusted	  hazard	  ratio	  
of	  8.5	  (95%	  CI=2.7–27;	  p=<0.001)	  and	  3.0	  (95%	  CI=1.3–7.0;	  p=0.016)	  
respectively	  (43).	  	  
Shipton	  et	  al	  performed	  a	  retrospective	  observational	  study	  in	  Botswana,	  
analysing	  all	  patients	  in	  HIV	  care	  at	  a	  hospital	  in	  Gaborone	  from	  2001	  to	  2004.	  
They	  included	  all	  patients	  who	  were	  initially	  TB	  treatment	  and	  ART	  naïve	  and	  
then	  started	  TB	  treatment	  during	  the	  study	  period	  and	  received	  concomitant	  
ART.	  The	  control	  group	  with	  similar	  distribution	  of	  HIV	  viral	  load	  values	  were	  
patients	  who	  received	  only	  ART	  treatment.	  TB	  treatment	  was	  initiated	  at	  a	  
median	  of	  81	  days	  prior	  to	  ART.	  There	  were	  more	  episodes	  of	  hepatotoxicity	  in	  
the	  group	  with	  concomitant	  TB	  treatment	  and	  ART	  as	  opposed	  to	  the	  ART-­‐only	  
group;	  9%	  vs.	  3%	  with	  p=0.05.	  Of	  note,	  there	  was	  no	  difference	  in	  rate	  of	  
hepatotoxicity	  between	  patients	  taking	  efavirenz	  or	  nevirapine-­‐based	  ART	  in	  
either	  group	  (44).	  	  
Chu	  et	  al	  analyzed	  data	  from	  three	  large	  primary	  care	  ART	  clinics	  in	  the	  Western	  
Cape	  province	  of	  South	  Africa	  to	  determine	  the	  occurrence	  of	  early	  











based	  ART.	  Early	  hepatotoxicity	  was	  defined	  as	  ALT	  grade	  0-­‐2	  at	  baseline,	  which	  
increased	  to	  grade	  3	  or	  4	  within	  102	  days	  of	  starting	  ART.	  Early	  hepatotoxicity	  
occurred	  with	  an	  incidence	  rate	  of	  3.6-­‐7.6	  per	  100	  person	  years	  at	  the	  102-­‐day	  
time	  point,	  depending	  on	  how	  regularly	  LFT’s	  were	  measured.	  Concurrent	  TB	  
treatment	  was	  not	  a	  risk	  factor	  for	  development	  of	  DILI	  in	  this	  study.	  The	  
number	  of	  patients	  on	  concurrent	  TB	  treatment	  is	  not	  mentioned	  in	  the	  study,	  
but	  4	  of	  the	  26	  cases	  of	  DILI	  occurred	  in	  patients	  on	  TB	  treatment	  (45).	  	  	  
Kalyesubula	  et	  al	  enrolled	  240	  ART-­‐naive	  patients	  prospectively	  in	  Uganda	  and	  
monitored	  liver	  function	  after	  starting	  ART.	  Two	  hundred	  and	  thirty	  eight	  
patients	  (99.2%)	  were	  receiving	  cotrimoxazole	  prophylaxis	  and	  13	  (5%)	  
received	  concomitant	  TB	  treatment.	  Patients	  on	  concomitant	  ART	  and	  TB	  
treatment	  were	  more	  likely	  to	  develop	  DILI	  with	  an	  odds	  ratio	  of	  16.0	  (95%	  CI;	  
2.4-­‐104.2,P<0.01)	  (46).	  
Mugusi	  et	  al	  performed	  a	  prospective	  study	  in	  Tanzania	  and	  classified	  473	  ART-­‐
naive	  HIV-­‐infected	  patients	  with	  CD4	  count	  <	  200	  cells/µL	  into	  2	  clinical	  
categories,	  HIV	  only	  (n=253)	  and	  HIV-­‐TB	  co-­‐infected	  (n=220).	  There	  were	  37	  
episodes	  of	  DILI	  of	  which	  22	  (10%	  incidence)	  occurred	  in	  the	  HIV-­‐TB	  co-­‐infected	  
group	  and	  15	  (5.9%	  incidence)	  in	  the	  HIV-­‐only	  group.	  This	  suggests	  more	  DILI	  in	  
HIV-­‐TB	  co-­‐infected	  patients	  although	  this	  difference	  was	  not	  statistically	  
significant	  (p-­‐value	  =	  0.07).	  Predictors	  of	  DILI	  in	  this	  cohort	  were	  chronic	  
hepatitis	  C	  infection,	  higher	  WHO	  stage	  at	  presentation,	  history	  of	  weight	  loss	  















The	  incidence	  of	  TB	  DILI	  in	  HIV-­‐infected	  and	  uninfected	  patients	  is	  not	  
frequently	  reported	  and	  varies	  (range	  0-­‐19.5%),	  depending	  on	  the	  definition	  for	  
DILI.	  	  Studies	  reporting	  the	  occurrence	  of	  TB	  DILI,	  which	  includes	  both	  HIV-­‐
infected	  and	  HIV	  uninfected	  participants,	  report	  conflicting	  data	  regarding	  HIV	  
as	  a	  risk	  factor	  for	  TB	  DILI.	  Some	  studies	  report	  HIV	  infection	  as	  an	  independent	  
risk	  factor	  for	  TB	  DILI	  and	  thus	  higher	  rates	  of	  TB	  DILI	  in	  HIV	  positive	  patients	  
(with	  estimates	  of	  roughly	  two-­‐fold	  increase	  among	  HIV-­‐infected),	  while	  other	  
studies	  report	  similar	  rates	  of	  TB	  DILI	  in	  the	  HIV-­‐infected	  and	  uninfected	  TB	  
patients.	  No	  obvious	  reason	  was	  found	  for	  this	  discrepancy	  in	  the	  literature	  
reviewed.	  Genetic	  factors	  and	  other	  differences	  between	  the	  populations	  studied	  
could	  be	  responsible	  for	  this	  discrepancy.	  	  	  
In	  studies	  including	  only	  HIV-­‐TB	  co-­‐infected	  patients	  several	  risk	  factors	  have	  
been	  identified	  to	  be	  independently	  associated	  with	  development	  of	  DILI	  across	  
different	  studies:	  female	  sex,	  concomitant	  TB	  treatment	  and	  ART,	  elevation	  of	  
baseline	  ALT	  and	  AST,	  fluconazole	  use,	  higher	  plasma	  efavirenz	  level,	  higher	  
efv/8-­‐hydroxyefavirenz	  ratio,	  lower	  baseline	  hemoglobin,	  lower	  serum	  albumin,	  
NAT2	  slow-­‐acetylator	  genotype	  and	  ABCB1	  3435TT	  genotype.	  However,	  only	  a	  
few	  studies	  have	  reported	  pharmacogenetic	  profiling	  of	  patients	  who	  develop	  
DILI.	  	  
Several	  studies	  which	  compared	  patients	  on	  ART	  alone	  to	  patients	  on	  ART	  and	  
TB	  treatment,	  report	  conflicting	  data	  regarding	  the	  risk	  of	  concomitant	  TB	  
treatment	  and	  ART	  for	  the	  development	  of	  DILI.	  All	  the	  studies	  assessed	  for	  this	  
aspect	  of	  the	  literature	  review	  were	  from	  the	  African	  continent	  and	  again	  there	  











to	  genetic	  and	  other	  differences	  between	  populations	  studied,	  or	  differences	  in	  
the	  case	  definitions	  used	  for	  DILI.	  	  	  
	  
Conclusion:	  
Drug	  induced	  liver	  injury	  is	  a	  poorly	  understood	  clinical	  entity	  and	  the	  cause	  of	  a	  
substantial	  burden	  of	  disease.	  Mechanisms	  by	  which	  most	  drugs	  cause	  liver	  
injury	  are	  unknown.	  Some	  risk	  factors	  for	  development	  of	  drug	  induced	  liver	  
injury	  have	  been	  described.	  However,	  more	  studies	  are	  needed	  to	  better	  define	  
mechanisms	  and	  risk	  factors	  for	  DILI.	  The	  role	  of	  HIV	  infection	  in	  development	  of	  
TB	  DILI	  and	  the	  role	  of	  concomitant	  TB	  treatment	  and	  ART	  in	  the	  development	  of	  
DILI	  need	  to	  be	  clarified.	  	  
	  
References:	  
1.	   UNAIDS.	  World	  Aids	  Day	  Report.	  Berlin/Geneva:	  UNAIDS2011.	  
2.	   WHO.	  Global	  Tuberculosis	  Control	  2011.	  	  2011	  [cited	  2011,	  14	  
November];	  Available	  from:	  
http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf.	  
3.	   Lawn	  SD,	  Bekker	  LG,	  Middelkoop	  K,	  Myer	  L,	  Wood	  R.	  Impact	  of	  HIV	  
infection	  on	  the	  epidemiology	  of	  tuberculosis	  in	  a	  peri-­‐urban	  community	  in	  
South	  Africa:	  the	  need	  for	  age-­‐specific	  interventions.	  Clin	  Infect	  Dis.	  2006	  Apr	  
1;42(7):1040-­‐7.	  
4.	   Boulle	  A,	  Van	  Cutsem	  G,	  Hilderbrand	  K,	  Cragg	  C,	  Abrahams	  M,	  Mathee	  S,	  et	  
al.	  Seven-­‐year	  experience	  of	  a	  primary	  care	  antiretroviral	  treatment	  programme	  
in	  Khayelitsha,	  South	  Africa.	  Aids.	  2010	  Feb	  20;24(4):563-­‐72.	  
5.	   UNAIDS	  &	  South	  African	  Department	  of	  Health.	  Country	  Progress	  Report	  




6.	   Tostmann	  A,	  Boeree	  MJ,	  Aarnoutse	  RE,	  de	  Lange	  WC,	  van	  der	  Ven	  AJ,	  
Dekhuijzen	  R.	  Antituberculosis	  drug-­‐induced	  hepatotoxicity:	  concise	  up-­‐to-­‐date	  
review.	  J	  Gastroenterol	  Hepatol.	  2008	  Feb;23(2):192-­‐202.	  
7.	   Montessori	  V,	  Press	  N,	  Harris	  M,	  Akagi	  L,	  Montaner	  JS.	  Adverse	  effects	  of	  
antiretroviral	  therapy	  for	  HIV	  infection.	  CMAJ.	  2004	  Jan	  20;170(2):229-­‐38.	  
8.	   Cohen	  K,	  Meintjes	  G.	  Management	  of	  individuals	  requiring	  antiretroviral	  











9.	   Pepper	  DJ,	  Marais	  S,	  Wilkinson	  RJ,	  Bhaijee	  F,	  Maartens	  G,	  McIlleron	  H,	  et	  
al.	  Clinical	  deterioration	  during	  antituberculosis	  treatment	  in	  Africa:	  incidence,	  
causes	  and	  risk	  factors.	  BMC	  Infect	  Dis.	  2010;10:83.	  
10.	   McIlleron	  H,	  Meintjes	  G,	  Burman	  WJ,	  Maartens	  G.	  Complications	  of	  
antiretroviral	  therapy	  in	  patients	  with	  tuberculosis:	  drug	  interactions,	  toxicity,	  
and	  immune	  reconstitution	  inflammatory	  syndrome.	  J	  Infect	  Dis.	  2007	  Aug	  
15;196	  Suppl	  1:S63-­‐75.	  
11.	   Bleibel	  W,	  Kim	  S,	  D'Silva	  K,	  Lemmer	  ER.	  Drug-­‐induced	  liver	  injury:	  review	  
article.	  Dig	  Dis	  Sci.	  2007	  Oct;52(10):2463-­‐71.	  
12.	   Saukkonen	  JJ,	  Cohn	  DL,	  Jasmer	  RM,	  Schenker	  S,	  Jereb	  JA,	  Nolan	  CM,	  et	  al.	  
An	  official	  ATS	  statement:	  hepatotoxicity	  of	  antituberculosis	  therapy.	  Am	  J	  Respir	  
Crit	  Care	  Med.	  2006	  Oct	  15;174(8):935-­‐52.	  
13.	   Lee	  WM.	  Drug-­‐induced	  hepatotoxicity.	  N	  Engl	  J	  Med.	  2003	  Jul	  
31;349(5):474-­‐85.	  
14.	   Yew	  WW,	  Leung	  CC.	  Antituberculosis	  drugs	  and	  hepatotoxicity.	  
Respirology.	  2006	  Nov;11(6):699-­‐707.	  
15.	   Navarro	  VJ,	  Senior	  JR.	  Drug-­‐related	  hepatotoxicity.	  N	  Engl	  J	  Med.	  2006	  Feb	  
16;354(7):731-­‐9.	  
16.	   Gunawan	  BK,	  Kaplowitz	  N.	  Mechanisms	  of	  drug-­‐induced	  liver	  disease.	  Clin	  
Liver	  Dis.	  2007	  Aug;11(3):459-­‐75,	  v.	  
17.	   South	  African	  Department	  of	  Health.	  National	  Tuberculosis	  Management	  
Guidelines	  2008.	  
18.	   Mitchell	  JR,	  Zimmerman	  HJ,	  Ishak	  KG,	  Thorgeirsson	  UP,	  Timbrell	  JA,	  
Snodgrass	  WR,	  et	  al.	  Isoniazid	  liver	  injury:	  clinical	  spectrum,	  pathology,	  and	  
probable	  pathogenesis.	  Ann	  Intern	  Med.	  1976	  Feb;84(2):181-­‐92.	  
19.	   Rivero	  A,	  Mira	  JA,	  Pineda	  JA.	  Liver	  toxicity	  induced	  by	  non-­‐nucleoside	  
reverse	  transcriptase	  inhibitors.	  J	  Antimicrob	  Chemother.	  2007	  Mar;59(3):342-­‐6.	  
20.	   Brinkman	  K,	  ter	  Hofstede	  HJ,	  Burger	  DM,	  Smeitink	  JA,	  Koopmans	  PP.	  
Adverse	  effects	  of	  reverse	  transcriptase	  inhibitors:	  mitochondrial	  toxicity	  as	  
common	  pathway.	  Aids.	  1998	  Oct	  1;12(14):1735-­‐44.	  
21.	   Mendes-­‐Correa	  MC,	  Andrade	  HF,	  Jr.,	  Fumica	  Takakura	  C,	  Seixas	  Duarte	  MI.	  
Hepatic	  ultrastructural	  mitochondrial	  changes	  prior	  to	  antiretroviral	  therapy	  in	  
HIV-­‐infected	  patients	   n	  Brazil.	  J	  Int	  Assoc	  Physicians	  AIDS	  Care.	  2008	  Sep-­‐
Oct;7(5):252-­‐8.	  
22.	   Tost	  JR,	  Vidal	  R,	  Cayla	  J,	  Diaz-­‐Cabanela	  D,	  Jimenez	  A,	  Broquetas	  JM.	  Severe	  
hepatotoxicity	  due	  to	  anti-­‐tuberculosis	  drugs	  in	  Spain.	  Int	  J	  Tuberc	  Lung	  Dis.	  
2005	  May;9(5):534-­‐40.	  
23.	   Schaberg	  T,	  Rebhan	  K,	  Lode	  H.	  Risk	  factors	  for	  side-­‐effects	  of	  isoniazid,	  
rifampin	  and	  pyrazinamide	  in	  patients	  hospitalized	  for	  pulmonary	  tuberculosis.	  
Eur	  Respir	  J.	  1996	  Oct;9(10):2026-­‐30.	  
24.	   Yee	  D,	  Valiquette	  C,	  Pelletier	  M,	  Parisien	  I,	  Rocher	  I,	  Menzies	  D.	  Incidence	  
of	  serious	  side	  effects	  from	  first-­‐line	  antituberculosis	  drugs	  among	  patients	  
treated	  for	  active	  tuberculosis.	  Am	  J	  Respir	  Crit	  Care	  Med.	  2003	  Jun	  
1;167(11):1472-­‐7.	  
25.	   Marzuki	  OA,	  Fauzi	  AR,	  Ayoub	  S,	  Kamarul	  Imran	  M.	  Prevalence	  and	  risk	  












26.	   de	  Castro	  L,	  do	  Brasil	  PE,	  Monteiro	  TP,	  Rolla	  VC.	  Can	  hepatitis	  B	  virus	  
infection	  predict	  tuberculosis	  treatment	  liver	  toxicity?	  Development	  of	  a	  
preliminary	  prediction	  rule.	  Int	  J	  Tuberc	  Lung	  Dis.	  2010	  Mar;14(3):332-­‐40.	  
27.	   Baghaei	  P,	  Tabarsi	  P,	  Chitsaz	  E,	  Saleh	  M,	  Marjani	  M,	  Shemirani	  S,	  et	  al.	  
Incidence,	  clinical	  and	  epidemiological	  risk	  factors,	  and	  outcome	  of	  drug-­‐induced	  
hepatitis	  due	  to	  antituberculous	  agents	  in	  new	  tuberculosis	  cases.	  Am	  J	  Ther.	  
2010	  Jan-­‐Feb;17(1):17-­‐22.	  
28.	   Tostmann	  A,	  van	  den	  Boogaard	  J,	  Semvua	  H,	  Kisonga	  R,	  Kibiki	  GS,	  
Aarnoutse	  RE,	  et	  al.	  Antituberculosis	  drug-­‐induced	  hepatotoxicity	  is	  uncommon	  
in	  Tanzanian	  hospitalized	  pulmonary	  TB	  patients.	  Trop	  Med	  Int	  Health.	  2010	  
Feb;15(2):268-­‐72.	  
29.	   Lorent	  N,	  Sebatunzi	  O,	  Mukeshimana	  G,	  Van	  den	  Ende	  J,	  Clerinx	  J.	  
Incidence	  and	  risk	  factors	  of	  serious	  adverse	  events	  during	  antituberculous	  
treatment	  in	  Rwanda:	  a	  prospective	  cohort	  study.	  PLoS	  One.	  2011;6(5):e19566.	  
30.	   Perriens	  JH,	  St	  Louis	  ME,	  Mukadi	  YB,	  Brown	  C,	  Prignot	  J,	  Pouthier	  F,	  et	  al.	  
Pulmonary	  tuberculosis	  in	  HIV-­‐infected	  patients	  in	  Zaire.	  A	  controlled	  trial	  of	  
treatment	  for	  either	  6	  or	  12	  months.	  N	  Engl	  J	  Med.	  1995	  Mar	  23;332(12):779-­‐84.	  
31.	   Chaisson	  RE,	  Clermont	  HC,	  Holt	  EA,	  Cantave	  M,	  Johnson	  MP,	  Atkinson	  J,	  et	  
al.	  Six-­‐month	  supervised	  intermittent	  tuberculosis	  therapy	  in	  Haitian	  patients	  
with	  and	  without	  HIV	  infection.	  Am	  J	  Respir	  Crit	  Care	  Med.	  1996	  Oct;154(4	  Pt	  
1):1034-­‐8.	  
32.	   Breen	  RA,	  Miller	  RF,	  Gorsuch	  T,	  Smith	  CJ,	  Schwenk	  A,	  Holmes	  W,	  et	  al.	  
Adverse	  events	  and	  treatment	  interruption	  in	  tuberculosis	  patients	  with	  and	  
without	  HIV	  co-­‐infection.	  Thorax.	  2006	  Sep;61(9):791-­‐4.	  
33.	   Yimer	  G,	  Aderaye	  G,	  Amogne	  W,	  Makonnen	  E,	  Aklillu	  E,	  Lindquist	  L,	  et	  al.	  
Anti-­‐tuberculosis	  therapy-­‐induced	  hepatotoxicity	  among	  Ethiopian	  HIV-­‐positive	  
and	  negative	  patients.	  PLoS	  One.2008;3(3):e1809.	  
34.	   Coca	  NS,	  Oliveira	  MS,	  Voieta	  I,	  Antunes	  CM,	  Lambertucci	  JR.	  
Antituberculosis	  drug-­‐induced	  hepatotoxicity:	  a	  comparison	  between	  patients	  
with	  and	  without	  human	  immunodeficiency	  virus	  seropositivity.	  Rev	  Soc	  Bras	  
Med	  Trop.	  2010	  Nov-­‐Dec;43(6):624-­‐8.	  
35.	   Dean	  GL,	  Edwards	  SG,	  Ives	  NJ,	  Matthews	  G,	  Fox	  EF,	  Navaratne	  L,	  et	  al.	  
Treatment	  of	  tuberculosis	  in	  HIV-­‐infected	  persons	  in	  the	  era	  of	  highly	  active	  
antiretroviral	  therapy.	  Aids.	  2002	  Jan	  4;16(1):75-­‐83.	  
36.	   Boeree	  MJ,	  Sauvageot	  D,	  Banda	  HT,	  Harries	  AD,	  Zijlstra	  EE.	  Efficacy	  and	  
safety	  of	  two	  dosages	  of	  cotrimoxazole	  as	  preventive	  treatment	  for	  HIV-­‐infected	  
Malawian	  adults	  with	  new	  smear-­‐positive	  tuberculosis.	  Trop	  Med	  Int	  Health.	  
2005	  Aug;10(8):723-­‐33.	  
37.	   Tostmann	  A,	  Boeree	  MJ,	  Harries	  AD,	  Sauvageot	  D,	  Banda	  HT,	  Zijlstra	  EE.	  
Short	  communication:	  antituberculosis	  drug-­‐induced	  hepatotoxicity	  is	  
unexpectedly	  low	  in	  HIV-­‐infected	  pulmonary	  tuberculosis	  patients	  in	  Malawi.	  
Trop	  Med	  Int	  Health.	  2007	  Jul;12(7):852-­‐5.	  
38.	   Pukenyte	  E,	  Lescure	  FX,	  Rey	  D,	  Rabaud	  C,	  Hoen	  B,	  Chavanet	  P,	  et	  al.	  
Incidence	  of	  and	  risk	  factors	  for	  severe	  liver	  toxicity	  in	  HIV-­‐infected	  patients	  on	  
anti-­‐tuberculosis	  treatment.	  Int	  J	  Tuberc	  Lung	  Dis.	  2007	  Jan;11(1):78-­‐84.	  
39.	   Moses	  M,	  Zachariah	  R,	  Tayler-­‐Smith	  K,	  Misinde	  D,	  Foncha	  C,	  Manzi	  M,	  et	  
al.	  Outcomes	  and	  safety	  of	  concomitant	  nevirapine	  and	  rifampicin	  treatment	  












40.	   Manosuthi	  W,	  Mankatitham	  W,	  Lueangniyomkul	  A,	  Chimsuntorn	  S,	  
Sungkanuparph	  S.	  Standard-­‐dose	  efavirenz	  vs.	  standard-­‐dose	  nevirapine	  in	  
antiretroviral	  regimens	  among	  HIV-­‐1	  and	  tuberculosis	  co-­‐infected	  patients	  who	  
received	  rifampicin.	  HIV	  Med.	  2008	  May;9(5):294-­‐9.	  
41.	   Mankhatitham	  W,	  Lueangniyomkul	  A,	  Manosuthi	  W.	  Hepatotoxicity	  in	  
patients	  co-­‐infected	  with	  tuberculosis	  and	  HIV-­‐1	  while	  receiving	  non-­‐nucleoside	  
reverse	  transcriptase	  inhibitor-­‐based	  antiretroviral	  therapy	  and	  rifampicin-­‐
containing	  anti-­‐tuberculosis	  regimen.	  Southeast	  Asian	  J	  Trop	  Med	  Public	  Health.	  
2011	  May;42(3):651-­‐8.	  
42.	   Yimer	  G,	  Ueda	  N,	  Habtewold	  A,	  Amogne	  W,	  Suda	  A,	  Riedel	  KD,	  et	  al.	  
Pharmacogenetic	  &	  pharmacokinetic	  biomarker	  for	  efavirenz	  based	  ARV	  and	  
rifampicin	  based	  anti-­‐TB	  drug	  induced	  liver	  injury	  in	  TB-­‐HIV	  infected	  patients.	  
PLoS	  One.	  2011;6(12):e27810.	  
43.	   Hoffmann	  CJ,	  Charalambous	  S,	  Thio	  CL,	  Martin	  DJ,	  Pemba	  L,	  Fielding	  KL,	  et	  
al.	  Hepatotoxicity	  in	  an	  African	  antiretroviral	  therapy	  cohort:	  the	  effect	  of	  
tuberculosis	  and	  hepatitis	  B.	  Aids.	  2007	  Jun	  19;21(10):1301-­‐8.	  
44.	   Shipton	  LK,	  Wester	  CW,	  Stock	  S,	  Ndwapi	  N,	  Gaolathe	  T,	  Thior	  I,	  et	  al.	  
Safety	  and	  efficacy	  of	  nevirapine-­‐	  and	  efavirenz-­‐based	  antiretroviral	  treatment	  in	  
adults	  treated	  for	  TB-­‐HIV	  co-­‐infection	  in	  Botswana.	  Int	  J	  Tuberc	  Lung	  Dis.	  2009	  
Mar;13(3):360-­‐6.	  
45.	   Chu	  KM,	  Boulle	  AM,	  Ford	  N,	  Goemaere	  E,	  Asselman	  V,	  Van	  Cutsem	  G.	  
Nevirapine-­‐associated	  early	  hepatotoxicity:	  incidence,	  risk	  factors,	  and	  
associated	  mortality	  in	  a	  primary	  care	  ART	  programme	  in	  South	  Africa.	  PLoS	  
One.	  2010;5(2):e9183.	  
46.	   Kalyesubula	  R,	  Kagimu	  M,	  Opio	  KC,	  Kiguba	  R,	  Semitala	  CF,	  Schlech	  WF,	  et	  
al.	  Hepatotoxicity	  from	  first	  line	  antiretroviral	  therapy:	  an	  experience	  from	  a	  
resource	  limited	  setting.	  Afr	  Health	  Sci.	  2011	  Mar;11(1):16-­‐23.	  
47.	   Mugusi	  S,	  Ngaimisi	  E,	  Janabi	  M,	  Minzi	  O,	  Bakari	  M,	  Riedel	  KD,	  et	  al.	  Liver	  
Enzyme	  Abnormalities	  and	  Associated	  Risk	  Factors	  in	  HIV	  Patients	  on	  Efavirenz-­‐















Table	  1:	  Observational	  studies	  that	  included	  HIV-­infected	  and	  HIV-­
uninfected	  patients	  (but	  HIV	  testing	  was	  not	  routinely	  done)	  and	  reported	  
tuberculosis	  treatment-­associated	  drug-­induced	  liver	  injury	  (TB	  DILI):	  	  
Reference	  
Country	  










519	   NR/9	   NR/191	   55	  (11%)	   NR	   No	  
(24)	  
Canada	  
430	   NR/18	   NR/149	   12	  (2.8%)	   NR	   1No	  
2(25)	  
Malaysia	  








46	  (9.7%)	   NR	   Yes	  
(26)	  
Brazil	  
154	   19/60	   11/94	   30	  (19.5%)	   29	  on	  ART3	   Yes	  
(27)	  
Iran	  
761	   7/43	   54/196	   99	  (13%)	   NR	   No	  
(28)	  
Tanzania	  











Legend	  for	  table	  1:	  
n=number	  of	  patients	  in	  study.	  
DILI:	  Drug	  induced	  liver	  injury	  
DILI	  Total:	  Drug	  induced	  liver	  injury	  cases	  in	  total.	  
NR=	  not	  reported.	  
1Not	  statistically	  significant	  with	  adjusted	  hazard	  ratio	  [aHR]=4.3	  (95%	  
confidence	  interval	  [CI]	  0.5	  –	  38).	  HIV	  was	  shown	  to	  be	  a	  risk	  factor	  for	  
development	  of	  grade	  3	  or	  4	  adverse	  events	  with	  aHR	  =3.8	  (95%	  CI	  1.05-­‐13.4)	  
2All	  cases	  of	  DILI	  were	  selected	  from	  the	  cohort	  and	  then	  controls	  were	  
randomly	  selected	  for	  a	  case	  control	  study.	  Nine	  out	  of	  46	  patients	  with	  DILI	  
were	  HIV-­‐infected	  and	  8	  out	  of	  138	  controls	  were	  HIV-­‐infected.	  
3All	  remaining	  patients	  except	  one	  started	  ART	 during	  TB	  treatment.	  	  
4HIV	  infection	  was	  an	  independent	  risk	  factor	  for	  development	  of	  serious	  
adverse	  events	  (not	  DILI	  specifically)	  with	  aHR	  =	  2.43	  (95%	  CI	  =	  1.35-­‐8.67;	  p-­‐











Table	  2:	  Studies	  that	  directly	  compared	  tuberculosis	  treatment-­associated	  
drug-­induced	  liver	  injury	  (TB	  DILI)	  in	  HIV-­infected	  and	  HIV-­uninfected	  
patients	  (HIV	  testing	  routinely	  done):	  	  
Reference	  
Country	  










523	   0/335	   0/188	   0	   None	   No	  
(31)	  
Haiti	  
427	   12%	  of	  177	   9%	  of	  250	   21%	  of	  427	   None	   No	  
(32)	  
United	  Kingdom	  
312	   20/156	   20/156	   40	   1111	   No	  
(33)	  
Ethiopia	  




162	   6/30	   12/132	   18	   NR	   No	  
Legend	  for	  table	  2:	  
n=number	  of	  patients	  in	  study	  
DILI:	  Drug	  induced	  liver	  injury	  
DILI	  Total:	  Drug	  induced	  liver	  injury	  cases	  in	  total	  
NR:	  Not	  reported	  
129	  on	  ART	  at	  the	  start	  of	  the	  study	  and	  82	  patients	  started	  on	  ART	  during	  study	  
at	  a	  median	  of	  2	  months	  after	  initiating	  TB	  treatment.	  
2Three	  different	  definitions	  for	  DILI	  were	  used	  in	  this	  paper.	  The	  number	  of	  











Table	  3:	  Identifying	  risk	  factors	  for	  DILI	  in	  HIV-­TB	  co-­infected	  patients:	  	  
Studies	  that	  included	  only	  HIV-­TB	  co-­infected	  patients:	  	  
Reference	  
Country	  
n	   ART	   DILI	  Total	   Factors	  associated	  with	  increased	  risk	  
to	  develop	  DILI	  
(35)	  
United	  Kingdom	  
188	   15%	  on	  ART;	  
45%	  started	  ART	  
during	  TB	  
treatment	  
11	  (5.9%)	   1Female	  sex:	  OR=2.03;	  95%	  CI	  1.09-­‐
3.77)	  
Concomitant	  TB	  treatment	  and	  ART:	  
OR=1.88;	  95%	  1.03-­‐3.42)	  	  
(37)	  
Malawi	  
579	   No	  ART	   28	  (1.4%)	   Not	  reported	  
(38)	  
France	  
144	   25	  on	  ART	   15	  (10.4%)	   Abnormal	  baseline	  ALT	  (p=0.028)	  and	  
BR	  levels	  (p=0.033)	  
Fluconazole	  use	  (p=0.008)	  
(39)	  
Malawi	  





3	  (2%)	   Not	  reported	  
(41)	  
Thailand	  
142	   All	  patients	  
started	  NVP	  or	  
EFV	  based	  ART	  




353	   All	  patients	  
started	  ART	  
within	  8	  weeks	  






3Female	  sex	  (p	  =	  0.001),	  	  
higher	  plasma	  EFV	  level	  (p	  =	  0.009),	  
efv/8-­‐hydroxyefavirenz	  ratio	  (p	  =	  
0.036),	  	  
raised	  baseline	  AST	  (p	  =	  0.022),	  and	  
ALT	  (p	  =	  0.014),	  	  
lower	  Hb	  (p	  =	  0.008),	  and	  serum	  Alb	  
(p	  =	  0.007),	  	  
NAT2	  slow-­‐acetylator	  genotype	  (p	  =	  
0.039)and	  	  
ABCB1	  3435TT	  genotype	  (p	  =	  0.001)	  
Legend	  for	  table	  3:	  
n=number	  of	  patients	  in	  study	  
ART:	  Antiretroviral	  therapy	  
DILI:	  Drug	  induced	  liver	  injury	  
DILI	  Total:	  Drug	  induced	  liver	  injury	  cases	  in	  total	  
OR:	  Odds	  ratio;	  aOR:	  Adjusted	  odds	  ratio	  
CI:	  Confidence	  interval	  
ALT:	  Alanine	  transaminase;	  BR:	  Bilirubin;	  AST:	  aspartate	  aminotransferase;	  	  
Alb:	  Albumin	  
NVP:	  Nevirapine;	  EFV:	  Efavirenz	  
HCV:	  Hepatitis	  C	  virus	  
BMI:	  Body	  mass	  index	  
Hb:	  Hemoglogin	  
1	  Predictors	  of	  adverse	  events	  reported	  in	  this	  study,	  not	  predictors	  of	  DILI.	  
2Grade	  2	  and	  3	  hepatotoxicity	  reported	  here.	  












Table	  4:	  Concomitant	  TB	  treatment	  as	  a	  risk	  factor	  for	  DILI	  in	  patients	  on	  












DILI	  Total	   Concomitant	  TB	  
treatment	  and	  ART	  a	  




868	   NR	   NR	   140	  	   Yes	  
(44)	  
Botswana	  
310	   3%	   9%	   18	   Yes	  
(45)	  
South	  Africa	  
1809	   22/?	   4/?	   26	   No	  
(46)	  
Uganda	  
240	   7/227	   3/13	   10	   Yes	  
(47)	  
Tanzania	  




37	  	   No	  
Legend	  for	  table	  4:	  
n=number	  of	  patients	  in	  study	  
ART:	  Antiretroviral	  therapy	  
DILI:	  Drug	  induced	  liver	  injury	  
TB:	  Tuberculosis	  
DILI	  Total:	  Drug	  induced	  liver	  injury	  cases	  in	  total	  
NR:	  Not	  reported	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An estimated 34 million people are HIV-infected globally; South 
Africa (SA) carries the highest burden with an estimated 5.6 million 
people infected.1 A major scale-up of public sector antiretroviral 
therapy (ART) has seen 1.4 million people start ART,2 and an 
increasing proportion of eligible individuals initiating treatment.3 
Tuberculosis (TB) case notifications per annum in SA reached 
396 554 in 2010, with 61% of incident TB cases HIV co-infected.4 
TB prevalence is high at initiation of ART: 2 clinics in Cape Town 
reported concomitant TB treatment (TBT) in 25% and 40% of 
patients, respectively, at time of ART initiation.5,6 In SA, 42% of HIV-
positive TB cases received both ART and TBT in 2009, compared 
with 18% in 2008.3
Drug-induced liver injury (DILI) is a well-recognised complication 
of TBT and ART. DILI is frequently encountered at healthcare 
facilities in SA and is especially challenging to manage in TB/HIV 
co-infected patients. Hepatotoxicity complicates TBT in 5 - 33% 
of patients.7 Studies reporting high rates include patients with 
subclinical elevations of liver enzymes. Depending on the regimen, 
hepatotoxicity develops in 9 - 30% of patients receiving ART.8 HIV 
infection itself is associated with an increased risk of major TBT 
side-effects.9 Liver dysfunction due to TBT or ART carries numerous 
risks, including: (i) direct morbidity and mortality due to liver failure, 
(ii) disease progression due to interruption of optimal therapy, (iii) 
complications of prolonged hospitalisation, and (iv) TBT or ART 
resistance related to interruptions.10 
G F Jooste Hospital (GFJH), a secondary-level referral hospital 
in Cape Town, serves communities with a high burden of TB/HIV 
co-infection. There has been a major scale-up of treatment services 
for both infections in the hospital’s catchment area in recent years. 
Patients from surrounding primary care HIV and TB clinics with 
adverse reactions to treatment of either disease, including significant 
symptoms or signs of liver injury, are referred for management to 
GFJH.
We aimed to assess the proportion of significant liver dysfunction 
caused by TBT and/or ART among patients with liver dysfunction 
presenting to a secondary hospital (GFJH), and to describe management 
and outcomes.
Methods
A retrospective observational study was conducted and results of all 
liver function tests (LFTs) performed at the GFJH National Health 
Burden of antituberculosis and antiretroviral drug-induced 
liver injury at a secondary hospital in South Africa
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Background. G F Jooste Hospital (GFJH) is a secondary-level referral 
hospital in a high HIV and tuberculosis (TB) co-infection setting. 
Aims. To assess the proportion of significant drug-induced 
liver injury (DILI) due to tuberculosis treatment (TBT) and/or 
antiretroviral therapy (ART) among patients presenting with liver 
dysfunction at GFJH and to describe management and outcomes. 
Methods. A retrospective observational study was performed of 
all cases referred to GFJH with significant liver dysfunction from 1 
January to 30 June 2009. Significant liver dysfunction was defined 
by alanine transaminase (ALT)≥200 U/l or total bilirubin (TBR)≥44 
µmol/l. TBT- or ART-associated DILI was defined as significant 
liver dysfunction attributed to TBT and/or ART and which resulted 
in the halting of treatment or the adjustment thereof. Outcome 
measures included case numbers, descriptive data, and in-hospital 
and 3-month mortality.
Results. A total of 318/354 cases of significant liver dysfunction 
were reviewed: 71 were classified as TBT- or ART-associated 
DILI, while liver dysfunction was attributed to other causes in 
the remainder. In-hospital and 3-month mortality of TBT- or 
ART-associated DILI patients was 27% (n=19) and 35% (n=25), 
respectively. The majority of deaths were related to sepsis or sepsis 
complicating liver dysfunction. Twenty-three patients (32%) were 
lost to follow-up; 23 (32%) were alive and in outpatient care 3 
months after presentation.
Conclusions. TBT- or ART-associated DILI is a common reason 
for presentation at a referral hospital in South Africa. In-hospital 
and 3-month mortality are high. Prospective studies are needed to 
define optimal management. 
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Laboratory Service laboratory from 1 January to 30 June 2009 were 
reviewed. Hepatocellular injury is characterised by a marked rise 
in serum transaminases, aspartate aminotransferase (AST) and 
alanine transaminase (ALT). Cholestatic liver injury is characterised 
by a rise in alkaline phosphatase, gamma-glutamyltransferase and/
or raised total bilirubin (TBR).11 Significant hepatocellular injury 
and cholestatic injury was defined as resulting in a Grade 3 or 4 
elevation of ALT≥200 U/l (>5 times the normal upper limit) and 
TBR≥44 µmol/l (>2.5 times the normal upper limit), respectively.12 
Patients who fulfilled one or both criteria were included. Sepsis was 
documented when clinical presentation was compatible and the 
admitting team managed infection as the primary cause of illness. 
Hepatic encephalopathy was documented by the admitting team. 
Patient records were reviewed and data recorded on a standardised 
form. DILI was attributed to TBT or ART if either regimen was 
interrupted or adjusted. Cases not classified as TBT- or ART-
associated DILI were classified as ‘liver dysfunction due to other 
causes’. This included: (i) patients receiving TBT and ART and 
diagnosed with hepatic TB-associated immune reconstitution 
inflammatory syndrome (TB-IRIS), (ii) patients presenting with 
untreated disseminated TB, (iii) patients receiving TBT and/or 
ART and presenting with liver injury with no subsequent change 
or discontinuation of TBT or ART, and (iv) patients diagnosed with 
alternative causes of liver dysfunction.
The University of Cape Town Human Research Ethics Committee 
approved the study (HREC ref: 522/2009). Statistical analyses were 
conducted with STATA 11.1 software (2009).
Management 
Patients receiving TBT and ART were managed at primary care 
clinics according to national treatment guidelines.13,14 Patients with 
significant symptoms or signs suggestive of DILI were referred to 
GFJH. Patients were admitted or managed as outpatients depending 
on clinical severity and LFT results. GFJH has an infectious diseases 
referral clinic with capacity to manage stable DILI patients as 
outpatients.
In patients with TBT-associated DILI, a decision was made to cease 
treatment temporarily or to switch to alternative and less hepatotoxic 
treatment. Cessation of TBT was defined as discontinuation of all 
TBT for longer than a day. In patients whose treatment had been 
interrupted, a less hepatotoxic regimen, typically consisting of 
streptomycin, ethambutol and ofloxacin, was usually commenced 
once LFT results improved. Rifampicin and isoniazid was then 
‘re-challenged’ in a stepwise manner after LFT results normalised. 
Rifampicin or isoniazid was started at a low dose and increased to 
full dose over a few days with concurrent monitoring of ALT. This 
was followed by similar introduction of the second drug. Once full-
dose rifampicin and isoniazid were re-introduced, certain of the less 
hepatotoxic drugs were discontinued. Optimal TBT was defined as 
rifampicin-based therapy.
Depending on the suspected cause and severity of ART-associated 
DILI, generally either: (i) ART was ceased, (ii) a single drug substitution 
was made, or (iii) more hepatotoxic ART (e.g. nevirapine) was interrupted 
and replaced within a few days (e.g. by efavirenz 5 - 7 days later), while 
less hepatotoxic ART (e.g. stavudine and lamivudine) was continued. 
Optimal ART was defined as triple ART medication from at least 2 
classes.
Outcome assessment
Clinical management and outcome data were ascertained by review 
of patient records. In-hospital and 3-month (within 90 days of 
presentation) mortality were recorded, including the cause of death 
where possible. Only in-hospital mortality was recorded for patients 
with liver injury due to other causes. Three-month retention in 
care was also recorded. In the case of TBT and/or ART-associated 
DILI, the Clinicom and eKapa electronic databases were consulted 
to ascertain follow-up and mortality documented elsewhere in the 
Western Cape. Loss to follow-up was defined as inability to trace any 
patient data after discharge, within 3 months of presentation.
Results
A total of 354 patients met the criteria for inclusion; 36 (10.2%) 
were excluded due to incomplete or missing records. Of 318 cases 
reviewed, 71 were classified as TBT- and/or ART-associated DILI. 
In 247 cases, liver injury was attributed to other causes (Fig. 1). 
Among many other causes of liver injury, the most common was 
sepsis-induced liver dysfunction, evident from clinical presentation 
and LFT results; 27 patients receiving TBT or ART were not 
diagnosed with TBT- or ART-associated DILI because no alteration 
was made to TBT or ART. 
Baseline characteristics
Of the 318 patients, 47% were women and 41% were HIV-infected 
(Table 1). At presentation, 18% were receiving ART, 26% were 
receiving TBT and 10% were receiving concomitant TBT and ART. 
ART regimens included: (i) stavudine (or zidovudine), lamivudine 
and efavirenz (n=17; 53%); (ii) stavudine (or zidovudine), lamivudine 
and nevirapine (n=9; 28%); and (iii) protease inhibitor (PI)-based 
ART (n=4; 13%). Three patients receiving TBT were treated with 
Fig. 1. Hepatitis or cholestasis: description of the cohort. TB = tuberculosis; 
TBT = TB treatment; ART = antiretroviral therapy; DILI = drug-induced 
liver injury.
*Twenty-seven (10%) patients in this group were also receiving TBT or ART, but patients 
presented with a syndrome suggestive of sepsis and were treated for sepsis with no 
adjustment to TBT or ART. 
†Patients presented with jaundice and diagnosis of disseminated TB was made during 
admission, i.e. patients were not receiving TBT or ART at presentation with liver 
dysfunction. Cause of jaundice was attributed to TB infiltration of the liver. 
‡Including gastro-intestinal tract malignancies, other malignancies with liver metastases, 
TB-associated immune reconstitution inflammatory syndrome, toxins, cardiac causes 
with liver congestion, unknown causes (not receiving TBT or ART) and a group of 
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PI-based ART and thus double-dose lopinavir/ritonavir. In the 
TBT- or ART-associated DILI category, a history of cotrimoxazole 
prophylaxis was available in 48/60 (80%) of the HIV-seropositive 
patients, and of these, 28 (47%) were receiving cotrimoxazole 
at presentation. Fifty-seven (80%) patients in this category were 
screened for hepatitis B surface antigen; 8 (14%) were positive. 
Clinical presentation and management 
Median length of hospital stay was 13 days (interquartile range (IQR) 
7 - 20) in the 87% of TBT- or ART-associated DILI patients who were 
admitted. Patients presented as follows: 56 (79%) with cholestasis 
(TBR≥44 µmol/l), 31 (44%) with hepatocellular injury (ALT≥200 U/l) 
and 18 (25%) with both. Fifteen (21%) had hepatic encephalopathy 
(Table 2). One or more possible alternate causes of liver dysfunction, 
including sepsis and TB-IRIS, were documented in 53 (75%) of 
patients. 
TBT was ceased in 29 (49%) patients, with a median of 16.5 (IQR 
14 - 26) days off optimal treatment. Less hepatotoxic TBT was initiated 
in 38 (64%) patients prior to re-challenge with rifampicin/isoniazid. 
Change in ART was individualised and varied widely. 
Optimal rifampicin-based TBT was not re-introduced in 27/59 
(45.8%) patients who presented while receiving TBT, for the following 
reasons: (i) death (n=14), (ii) transfer to another facility without 
particulars of subsequent re-challenge (n=5), (iii) absence of evidence 
for initial TB diagnosis (n=4), (iv) discharge with less hepatotoxic TBT 
and intention to re-challenge at a later stage (n=2), (v) presentation of 
DILI while receiving less hepatotoxic TBT which was continued while 
ART was adjusted (i.e. managed as ART-associated DILI) (n=1), (vi) 
completion of TBT (n=1), or (vii) patient absconded (n=1).
ART was interrupted in 11 patients (34%) and altered in 23 (74%). 
Patients spent a median of 25 (IQR 7 - 40) days off optimal ART 
(triple therapy). In 27 (38%) TBT- or ART-associated DILI patients, 
additional investigations were performed, including abdominal 
ultrasound (n=24), computed tomography (CT) of the abdomen 
(n=2), and liver biopsy (n=1; performed during DILI relapse). 
Patients who were discharged and followed up as outpatients 
(n=21, 29.6%) had a median of 4.5 visits in the 3 months following 
presentation. Seven (9.9%) patients had subsequent relapse of hepatitis 
Table 1. Baseline characteristics of patients who presented with cholestasis or hepatitis
Total (N=318) TB or ART* (n=71) Other (n=247)
Age (years), median (IQR) 39 (30 - 50) 39 (30 - 43) 39 (29 - 54)
Sex: female, n (%) 165 (51.9) 44 (62) 121 (49)
HIV Status
Tested for HIV, n (%) 190 (59.7) 69 (97.2) 121 (49)
HIV-positive, n (%) 144 (45.3) 60 (84.5) 84 (34)
HIV-negative, n (%) 46 (14.5) 9 (12.7) 37 (15)
CD4 count, median (IQR) 59 (26 - 179) 75 (28 - 189) 57 (26 - 174)
Tested for hepatitis B surface antigen,§ n (%) - 57 (80.3) -
Positive, n (%) - 8 (11.3) -
Receiving ART at presentation,¶ n (%) 63 (19.8) 32 (45.1) 31 (12.6)
Days of ART, median (IQR) 60 (30 - 251) 41 (29 - 81) 105 (38 - 565)
Receiving TBT at presentation, n (%) 92 (28.9) 59 (83.1) 33 (13.4)
Days of TBT, median (IQR) 56 (20 - 129) 40 (15 - 89)|| 99 (32.5 - 158.5)
Regimen I TBT,† n (%) 62 (19.5) 44 (62)** 18 (54.6)
Regimen II TBT,‡ n (%) 25 (7.8) 12 (17) 13 (39.4)
Concomitant TBT and ART, n (%) 36 (11.3) 20 (28.2) 16 (6.5)
Cotrimoxazole prophylaxis documented,†† n (%) 127 (39.9) 48 (67.6) 79 (32)
Receiving cotrimoxazole, n (%) 59 (18.6) 28 (39.4) 31 (12.6)
*Patients with TBT- and/or ART-associated DILI. 
†Regimen I TBT: 2 months of rifampicin, isoniazid, pyrazinamide and ethambutol, followed by 4 months of rifampicin and isoniazid.
‡Regimen II TBT: 2 months of rifampicin, isoniazid, pyrazinamide, ethambutol and streptomycin, followed by 1 month of rifampicin, isoniazid, pyrazinamide and ethambutol, followed by 5 
months of rifampicin, isoniazid and ethambutol.
§Data were only captured for TBT- or ART-associated DILI.
¶TBT- or ART-associated DILI: 11 known HIV-infected patients with no available information about ART use. Other causes: 1 known HIV-infected patient with no available information about ART use. 
||
8 patients with TBT- or ART-associated DILI: unknown duration of TBT.
**
11 patients with TBT- or ART-associated DILI: unknown TB regimen.
††
Cotrimoxazole prophylaxis documented in known HIV-infected patients. 
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Table 2. Clinical presentation and management of TBT- or ART-associated DILI patients
TBT- or ART-associated DILI (N=71)
Admitted to hospital, n (%) 62 (87.3)
Days in hospital, median (IQR) 13 (7 - 20)
Laboratory results at presentation
AST (U/l), median (IQR) 245 (117 - 628)
ALT (U/l), median (IQR) 157 (71 - 353)
Patients with ALT≥200 U/l, n (%) 31 (43.6)
GGT (U/l), median (IQR) 108 (61 - 292)
ALP (U/l), median (IQR) 110 (80 - 231)
TBR (µmol/l), median (IQR) 88 (50 - 128)
Patients with TBR≥44 µmol/l, n (%) 56 (78.9)
Patients with ALT≥200 U/l and TBR≥44 µmol/l, n (%) 18 (25.4)
INR performed at presentation, n (%) 42 (59.2)
INR, median (IQR)* 1.7 (1.3 - 3)
Clinical features
Hepatic encephalopathy, n (%) 15 (21.1)
Case fatality rate,† n (%) 8 (53.3)
Differential diagnosis,‡ n (%) 53 (74.7)
Number of differential diagnoses,§ median (range) 2 (1 - 3)
Patients receiving TBT, n (%) 59 (83)
Treatment completely interrupted, n (%) 29 (49.2)
Less hepatotoxic TBT initiated, n (%) 38 (64.4)
TB medication restarted,¶ n (%) 32 (54.2)
Days off optimal TBT,|| median (IQR) 16.5 (14 - 26)
Patients receiving ART, n (%) 32 (45)
Treatment completely interrupted, n (%) 11 (34.4)
Any change made to ART,** n (%) 23 (71.9)
Days off optimal ART,†† median (IQR) 25 (7 - 40)
Additional investigations performed, n (%) 27 (38)
USS abdomen 24 (33.8)
CT abdomen 2 (2.8)
Liver biopsy‡‡ 1 (1.4)
Outpatient follow-up visits,§§ median (IQR) 4.5 (3 - 7)
Relapse of hepatitis or cholestasis, n (%) 7 (9.9)
Admitted to hospital, n (%) 5 (7)
Days in hospital, median (IQR) 12 (12 - 21)
Outpatient follow-up visits following relapse,§§ median (IQR) 6 (5 - 8)
AST = aspartate aminotransferase; ALT = alanine transaminase; GGT = gamma-glutamyltransferase; ALP = alkaline phosphatase; TBR = total bilirubin; INR = international normalised ratio.
*Five (7.35%) patients had other reason contributing to high INR: warfarin therapy (n=2) and congestive cardiac failure (n=3). 
†Case fatality rate in patients who presented with hepatic encephalopathy.
‡Patients who had significant differential diagnoses at time of DILI.
§Significant differential diagnoses per patient.
¶Rifampicin and isoniazid restarted.
|| Rifampicin-based TBT.
**Including ART completely stopped.
††Triple therapy ART.
‡‡One patient had a liver biopsy at subsequent relapse of hepatitis.
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or cholestasis; 5 (71.4%) were re-admitted to hospital for a median of 
12 days (IQR 12 - 21); 1 died in hospital due to sepsis and 6 were alive 
and in care 3 months after presentation of relapse. 
Patient outcomes 
The Kaplan-Meier survival estimate is shown in Fig. 3. In-hospital 
mortality of the cohort was 27% (n=19) and 53% in patients who 
presented with hepatic encephalopathy. Common causes of death 
during initial admission included sepsis, a combination of sepsis and 
active TB or DILI, and liver failure (Fig. 2). Three of 19 in-hospital deaths 
occurred after completion of TBT re-challenge; causes were sepsis (2) 
and unknown (1, unexpected death after initial improvement). At 3 
months after presentation, 25 (35%) patients had died, 23 (32%) were 
alive and in care, and 23 (32%) were lost to follow-up (Table 3). 
In cases of ‘liver dysfunction due to other causes’, 71 (28.7%) 
patients died during admission. This included 34 patients admitted 
with sepsis, of whom 14 were receiving TBT or ART.
Discussion
To our knowledge, this is the first study describing the management, 
outcome and high burden of TBT- or ART-associated DILI at a referral 
hospital in a high TB/HIV prevalence community. Over 6 months there 
were 71 cases. This may reflect under-ascertainment, accepting that – 
in the absence of a confirmatory test for DILI – some patients admitted 
with TBT- or ART-associated DILI would have been misclassified as 
having other causes of liver dysfunction such as TB-IRIS or sepsis. 
TBT was a frequent cause of DILI in our study. TBT-attributed DILI 
may reduce TBT effectiveness due to a negative effect on adherence, 
treatment interruption and substitution with less effective TB medication. 
TBT-associated DILI may be fatal if not recognised and managed early.10 
We attributed DILI to ART in 23/32 patients receiving such 
therapy. Medication of both first- and second-line ART regimens 
may cause DILI. Nucleoside reverse transcriptase inhibitors 
(NRTIs) may cause fatty liver related to mitochondrial toxicity. 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) cause 
liver injury related to immune-mediated hypersensitivity. The 
mechanism of PI-induced DILI is ot entirely understood.8 In 
patients receiving lopinavir/ritonavir, additional ritonavir or 
double-dose lopinavir/ritonavir is required to counteract rifampicin 
induction, and high incidence of hepatotoxicity has been reported 
in such patients.15,16 Three patients were receiving lopinavir/
ritonavir-based ART and TBT; 2 were alive and in care 3 months 
after presentation and 1 was lost to follow-up.
Twenty patients were on concomitant rifampicin-based TBT and 
ART, which have overlapping toxicities. The cause of liver dysfunction 
in these patients is likely multi-factorial. The pathogenic mechanisms 
of DILI are complex, unpredictable and related to medication 
and genetic factors.11,17 Management is complex and needs to be 
individualised. TBT or ART was ceased or altered in all 20 cases, 
leading to prolonged hospital admission for drug re-challenge and 
increased vulnerability to disease progression and other infections. 
There are considerable risks associated with prolonged hospital stay 
in the context of advanced HIV infection, particularly nosocomial 
sepsis.18 We observed more cases of DILI related to TBT alone (n=39) 
than with ART alone (n=12) or concomitant ART and TBT (n=20), 
possibly reflecting that more patients were initiated on TBT than 
on ART in the hospital catchment area during the study period. 
Alternatively, TBT may be a more common cause of DILI.
Adding to the complexity, cotrimoxazole may also cause DILI; 
prophylactic treatment is often stopped during management of DILI, 
rendering patients vulnerable to opportunistic infections. Chronic 
hepatitis B is also an important co-factor in DILI; concomitant TBT 
significantly increases the risk of hepatotoxicity.19 Hepatitis B surface 
antigen was positive in a minority of cases in our study; 8/57 patients 
with TBT- or ART-associated DILI.
A striking finding was the high mortality associated with TBT- or 
ART-associated DILI (35% at 3 months after presentation) with a 
median time to death of 11 days (IQR 5 - 31). Mortality was likely 
under ascertained, as it is possible that some patients recorded as lost 
to follow-up really died. In comparison, mortality in a general cohort 
of patients with HIV-associated TB in our setting was only 8% during 
6 months of TBT.20 
In our study, the most common cause of death ascertained was 
sepsis, highlighting the vulnerability of patients with liver injury to 
bacterial and other infections. Close monitoring for community- 
and hospital-acquired bacterial infections and early diagnosis with 
appropriate antimicrobial treatment may improve outcome. Liver 
failure was the cause of death in only a minority of cases. Further 
studies are required to define reasons for the high mortality among 
DILI patients; this rate may reflect direct and indirect consequences Fig. 3. Kaplan-Meier survival estimate in TBT- or ART-associated DILI.
Table 3. Three-month outcomes of TB- or ART-associated DILI patients* (N=71)
n (%) Days,† median (IQR)
Died during initial admission§ 19 (26.8) 8 (3 - 13)
Discharged; died within 3 months of presentation 6   (8.5) 59.5 (56 - 70)
Lost to follow-up within 3 months of presentation‡ 23 (32.4) 42 (18 - 57)
Discharged, alive and in care 3 months after presentation 23 (32.4) -
*Three months or 90 days from presentation with hepatitis or cholestasis. 
†Days from presentation with hepatitis or cholestasis until death or loss to follow up.
‡Lost to follow-up: no patient record available after discharge.  
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of DILI, or that DILI complicates poor prognoses owing to other 
disease-related factors. 
We acknowledge several limitations of our study. The use of 
herbal, traditional or over-the-counter medication, all of which 
may cause liver injury, was poorly documented. A retrospective 
review has many limitations: data capture was limited to 
documentation by attending clinicians and 10% of records were 
not found for review. 
Conclusions
Liver injury due to TBT- or ART-associated DILI necessitating 
referral to hospital was common and associated with high mortality 
in our study. The cause of liver injury in HIV-TB co-infected patients 
is likely multi-factorial and is complex to manage. Prospective studies 
are urgently needed to investigate optimal management strategies 
and improve outcomes of such patients. The use of early invasive 
investigations (e.g. liver biopsy) in the diagnosis and management of 
liver injury requires investigation. 
Acknowledgements. Sources of support: Perinatal HIV Research Unit, the 
US Agency for International Development, and the President’s Emergency 
Plan for AIDS Relief (SM and CS), Wellcome Trust (RJW and GM, WT 
081667, 084323 and 088316); a Fogarty International Center South Africa 
TB/AIDS Training Award (GM and CS, NIH/FIC 1U2RTW007373-
01A1, U2RTW007373 ICORTA); a European Union Grant (RJW, 
SANTE/2005/105-061-102); and MRC (RJW, U1175.02.002.00014.01). 
The funders had no role in study design, data collection and analysis, 
decision to publish, or manuscript preparation.
References
1. UNAIDS. World Aids Day Report. Berlin/Geneva: UNAIDS, 2011. http://www.unaids.org/en/media/
unaids/contentassets/documents/unaidspublication/2011/JC2216_WorldAIDSday_report_2011_
en.pdf  (accessed 3 January 2012).
2. Motsoaledi A. How we’re re-engineering the health system. Johannesburg: Politicsweb, 2011. http://
www.politicsweb.co.za/politicsweb/view/politicsweb/en/page71656?oid=238984&sn=Detail&p
id=71616 (accessed 14 November 2011).
3. UNAIDS Republic of South Africa Country Progress Report on the Declaration of Commitment on 
HIV/AIDS. Berlin/Geneva: UNAIDS, 2010. http://www.unaids.org/en/dataanalysis/monitoringcoun
tryprogress/2010progressreportssubmittedbycountries/southafrica_2010_country_progress_report_
en.pdf  (accessed 14 November 2011). 
4. WHO. Global Tuberculosis Control 2011. Geneva: WHO, 2011. http://www.who.int/tb/publications/
global_report/2011/gtbr11_full.pdf (accessed 14 November 2011).
5. Lawn SD, Bekker LG, Middelkoop K, Myer L, Wood R. Impact of HIV infection on the epidemiology 
of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. 
Clin Infect Dis 2006;42(7):1040-1047.
6. Boulle A, Van Cutsem G, Hilderbrand K, et al. Seven-year experience of a primary care antiretroviral 
treatment programme in Khayelitsha, South Africa. AIDS 2010;24(4):563-572.
7. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis 
therapy. Am J Respir Crit Care Med 2006;174(8):935-952.
8. Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for 
HIV infection. CMAJ.2004;170(2):229-238.
9. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis 
drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167(11):1472-1477.
10. Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise 
up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192-202.
11. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354(7):731-739.
12. DAIDS. Table for Grading Adult and Pediatric Adverse Events. Version 1.0. 2004.  http://rsc.tech-
res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_
Adverse_Events.pdf (accessed 28 December 2011).
13. Department of Health (DoH). National Tuberculosis Management Guidelines 2008. Pretoria: DoH, 
2008. http://www.sasohn.org.za/images/TBGUIDELINES2008SFINALFORPRINTINGMARCH09.
pdf (accessed 28 December 2011).
14. Department of Health. National Antiretroviral Treatment Guidelines. Johannesburg: Jacana, 2004.
15. Nijland HM, L’Homme RF, Rongen GA, et al. High incidence of adverse events in healthy volunteers 
receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 2008;22(8):931-935.
16. Cohen K, Meintjes G. Management of individuals requiring antiretroviral therapy and TB treatment. 
Curr Opin HIV AIDS 2010;5(1):61-69.
17. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced 
hepatotoxicity. Curr Med Chem 2009;16(23):3041-3053.
18. Pepper DJ, Rebe K, Morroni C, Wilkinson RJ, Meintjes G. Clinical deterioration during antitubercular 
treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining 
illnesses. PLoS One 2009;4(2):e4520.
19. Hoffmann CJ, Charalambous S, Thio CL, et al. Hepatotoxicity in an African antiretroviral therapy 
cohort: the effect of tuberculosis and hepatitis B. AIDS 2007;21(10):1301-1308.
20. Pepper DJ, Marais S, Wilkinson RJ, et al. Clinical deterioration during antituberculosis treatment in 
Africa: Incidence, causes and risk factors. BMC Infect Dis 2010;10:83.
Accepted 27 January 2012.
FACULTY OF HEALTH SCIENCES










SAMJ: South African Medical Journal 
Submissions 
• » Online Submissions 
• » Author Guidelines 
• » Copyright Notice 
• » Privacy Statement 
Online Submissions 
Already have a Username/Password for South African Medical Journal? 
Go to Login  
Need a Username/Password? 
Go to Registration  




Accepted manuscripts that are not in the correct format specified in these guidelines will be 
returned to the author(s) for correction, and will delay publication. 
 
AUTHORSHIP 
Named authors must consent to publication. Authorship should be based on substantial contribution to: 
(i) conception, design, analysis and interpretation of data; (ii) drafting or critical revision for important 
intellectual content; and (iii) approval of the version to be published. These conditions must all be met 
(uniform requirements for manuscripts submitted to biomedical journals; refer to www.icmje.org). 
 
CONFLICT OF INTEREST 
Authors must declare all sources of support for the research and any association with a product or 
subject that may constitute conflict of interest. 
 
RESEARCH ETHICS COMMITTEE APPROVAL 
Provide evidence of Research Ethics Committee approval of the research where relevant. 
 
PROTECTION OF PATIENT'S RIGHTS TO PRIVACY 
Identifying information should not be published in written descriptions, photographs, and pedigrees 
unless the information is essential for scientific purposes and the patient (or parent or guardian) gives 
informed written consent for publication. The patient should be shown the manuscript to be published. 
Refer to www.icmje.org. 
 
ETHNIC CLASSIFICATION 
References to ethnic classification must indicate the rationale for this. 
 
MANUSCRIPTS 
Shorter items are more likely to be accepted for publication, owing to space constraints and reader 
preferences.  
 
Research articles (previously 'Original articles') not exceeding 3 000 words, with up to 6 tables or 
illustrations, are usually observations or research of relevance to clinical medicine and related fields. 
References should preferably be limited to no more than 15. Please provide a structured abstract not 
exceeding 250 words, with the following recommended headings: Background, Objectives, Methods, 
Results, and Conclusion. 
 
Scientific letters will, in future, be incorporated as shorter Research articles.  
 
Editorials, Opinions, etc. should be about 1000 words and are welcome, but unless invited, will be 
subjected to the SAMJ peer review process. 
 
Review articles are rarely accepted unless invited. 
 










must include a correspondence address.  
 
Forum articles must be accompanied by a short description (50 words) of the affiliation 
details/interests of the author(s). Refer to recent forum articles for guidance. Please provide an 
accompanying abstract not exceeding 150 words.  
 
Book reviews should be about 400 words and must be accompanied by the publication details of the 
book.  
 
Obituaries should be about 400 words and may be accompanied by a photograph. 
 
MANUSCRIPT PREPARATION 
Refer to articles in recent issues for the presentation of headings and subheadings. If in doubt, refer to 
'uniform requirements' - www.icmje.org. 
 
Manuscripts must be provided in UK English. 
 
Qualification, affiliation and contact details of ALL authors must be provided in the manuscript and 
in the online submission process. 
 
Abbreviations should be spelt out when first used and thereafter used consistently, e.g. 'intravenous 
(IV)' or 'Department of Health (DoH)'. 
 
Scientific measurements must be expressed in SI units except: blood pressure (mmHg) and 
haemoglobin (g/dl). Litres is denoted with a lowercase 'l' e.g. 'ml' for millilitres). Units should be 
preceded by a space (except for %), e.g. '40 kg' and '20 cm' but '50%'. Greater/smaller than signs (> and 
<) should be placed immediately preceding the relevant number, i.e. 'women >40 years of age'. The 
same applies to ± and º, i.e. '35±6' and '19ºC'. 
 
Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160... 
 
Quotes should be placed in single quotation marks: i.e. The respondent stated: '...' 
 
Round brackets (parentheses) should be used, as opposed to square brackets, which are reserved for 
denoting concentrations or insertions in direct quotes. 
 
General formatting 
The manuscript must be in Microsoft Word or RTF document format. Text must be single-spaced, in 
12-point Times New Roman font, and contain no unnecessary formatting (such as text in boxes, with 
the exception of Tables). 
 
ILLUSTRATIONS AND TABLES 
If tables or illustrations submitted have been published elsewhere, the author(s) should provide consent 
to republication obtained from the copyright holder.  
 
Tables may be embedded in the manuscript or provided as 'supplementary files'. Tables must be 
numbered in Arabic numerals (1,2,3...) and referred to in the text (e.g. 'Table 1'). Table footnotes must 
be indicated with the use of the following symbols (in order): * † ‡ § ¶ || then ** †† ‡‡ etc. 
 
Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'. Figure legends: 
Fig. 1. 'Title...' 
 
All illustrations/figures/graphs must be of high resolution/quality: 300 dpi or more is preferable but 
images must not be resized to increase resolution. Unformatted and uncompressed images must be 
attached as 'supplementary files' upon submission (not embedded in the accompanying manuscript). 
TIFF and PNG formats are preferable; JPEG and PDF formats are accepted, but authors must be wary 
of image compression. Illustrations and graphs prepared in Microsoft Powerpoint or Excel must be 












Authors must verify references from the original sources. Only complete, correctly formatted reference 
lists will be accepted. Reference lists must be generated manually and not with the use of reference 
manager software.  
 
References should be inserted in the text as superscript numbers, e.g. These regulations are endorsed by 
the World Health Organization,2 and others.3,4,6 
 
All references should be listed at the end of the article in numerical order of appearance in the 
Vancouver style (not alphabetical order). Approved abbreviations of journal titles must be used; see 
the List of Journals in Index Medicus.  
 
Names and initials of all authors should be given; if there are more than six authors, the first three 
names should be given followed by et al. First and last page, volume and issue numbers should be 
given. 
 
Wherever possible, references must be accompanied by a digital object identifier (DOI) link and 
PubMed ID (PMID)/PubMed Central ID (PMCID). Authors are encouraged to use the DOI lookup 
service offered by CrossRef. 
 
Journal references: 
Price NC, Jacobs NN, Roberts DA, et al. Importance of asking about glaucoma. Stat Med 
1998;289:350-355. [http://dx.doi.org/10.1000/hgjr.182] [PMID: 2764753] 
 
Book references: 
Jeffcoate N. Principles of Gynaecology. 4th ed. London: Butterworth, 1975:96-101.  
 
Chapter/section in a book: 
Weinstein L, Swartz MN. Pathogenic properties of invading microorganisms. In: Sodeman WA jun, 




World Health Organization. The World Health Report 2002 - Reducing Risks, Promoting Healthy Life. 
Geneva: World Health Organization, 2002. http://www.who.int/whr/2002 (accessed 16 January 2010). 
 
Other references (e.g. reports) should follow the same format: 
Author(s). Title. Publisher place: publisher name, year; pages.  
 
Cited manuscripts that have been accepted but not yet published can be included as references followed 
by '(in press)'.  
 
Unpublished observations and personal communications in the text must not appear in the reference 
list. The full name of the source person must be provided for personal communications e.g. '...(Prof. 
Michael Jones, personal communication)'. 
 
PROOFS  
PDFs may be sent to the author before publication to resolve any remaining query. 
 
CHANGES OF ADDRESS 




Authors can earn up to 15 CPD CEUs for published articles. Certificates may be requested after 
publication of the article. 
 
CHARGES 
There is no charge for the publication of manuscripts. 
  










As part of the submission process, authors are required to check off their submission's compliance with 
all of the following items, and submissions may be returned to authors that do not adhere to these 
guidelines. 
1. Named authors consent to publication and meet the requirements of authorship as set out by 
the journal. 
2. The submission has not been previously published, nor is it before another journal for 
consideration. 
3. The text complies with the stylistic and bibliographic requirements in Author Guidelines. 
4. The manuscript is in Microsoft Word or RTF document format. The text is single-spaced, in 
12-point Times New Roman font, and contains no unnecessary formatting. 
5. Illustrations/figures are high resolution/quality (not compressed) and in an acceptable format 
(preferably TIFF or PNG). These must be submitted as 'supplementary files' (not in the 
manuscript). 
6. For illustrations/figures or tables that have been published elsewhere, the author has obtained 
written consent to republication from the copyright holder. 
7. Where possible, references are accompanied by a digital object identifier (DOI) and PubMed 
ID (PMID)/PubMed Central ID (PMCID). 
8. An abstract has been included where applicable. 
9. The research was approved by a Research Ethics Committee (if applicable) 
10. Any conflict of interest (or competing interests) is indicated by the author(s). 
  
Copyright Notice 
The South African Medical Journal (SAMJ) reserves copyright of the material published. The work is 
licensed under a Creative Commons Attribution - Noncommercial Works License. 
 
Material submitted for publication in the SAMJ is accepted provided it has not been published 
elsewhere. 
 
The SAMJ does not hold itself responsible for statements made by the authors. 
  
Privacy Statement 
The names and email addresses entered in this journal site will be used only for the stated purposes of 












PART	  D:	  Appendices:	  
a.	  Acknowledgements:	  
Co-­‐authors:	  	  
Graeme	  Meintjes,	  Robert	  J	  Wilkinson,	  Gary	  Maartens,	  Suzaan	  Marais,	  Rosie	  
Burton	  and	  Chris	  Kenyon	  were	  all	  involved	  with	  study	  conception	  and	  planning	  
of	  the	  study.	  Zahiera	  Ismail	  and	  Charles	  John	  Proxenos	  assisted	  with	  design	  and	  
piloting	  of	  the	  data	  capture	  sheets.	  They	  also	  helped	  to	  capture	  data	  and	  with	  
data	  entry.	  	  Graeme	  Meintjes	  and	  Suzaan	  Marais	  helped	  with	  reviews	  of	  the	  first	  
rough	  drafts	  of	  the	  paper	  and	  Suzaan	  Marais	  helped	  with	  extensive	  reviewing	  of	  
the	  second	  last	  draft	  of	  the	  paper.	  	  Graeme	  Meintjes	  reviewed	  the	  final	  draft	  
extensively.	  This	  final	  draft	  was	  then	  reviewed	  by	  all	  co-­‐authors	  and	  extensive	  
input	  was	  given	  to	  finalize	  the	  paper	  for	  submission.	  All	  co-­‐authors’	  comments	  
were	  incorporated	  into	  the	  paper	  prior	  to	  submission.	  	  
	  
Sources	  of	  financial	  support	  (no	  support	  was	  specifically	  for	  this	  study):	  
Perinatal	  HIV	  Research	  Unit,	  the	  US	  Agency	  for	  International	  Development,	  and	  
the	  President’s	  Emergency	  Plan	  for	  AIDS	  Relief	  (Suzaan	  Marais	  and	  Charlotte	  
Schutz).	  Wellcome	  Trust	  (Robert	  J	  Wilkinson	  and	  Graeme	  Meintjes,	  WT	  081667,	  
084323	  and	  088316).	  Fogarty	  International	  Center	  South	  Africa	  TB/AIDS	  
Training	  Award	  (Graeme	  Meintjes	  and	  Charlotte	  Schutz,	  NIH/FIC	  
1U2RTW007373-­‐	  01A1,	  U2RTW007373	  ICORTA).	  A	  European	  Union	  Grant	  
(Robert	  J	  Wilkinson,	  SANTE/2005/105-­‐061-­‐102).	  MRC	  (Robert	  J	  Wilkinson,	  
U1175.02.002.00014.01).	  The	  funders	  had	  no	  role	  in	  study	  design,	  data	  











Thank	  you:	  	  
I	  would	  like	  to	  extend	  a	  special	  thank	  you	  to	  my	  supervisor	  Graeme	  Meintjes	  for	  
all	  his	  patient	  support,	  advice	  and	  review	  of	  material	  throughout	  this	  project.	  
Also	  to	  all	  my	  lecturers	  throughout	  the	  MPH	  (Clinical	  Research)	  course	  who	  have	  
taken	  the	  time	  to	  teach	  me	  the	  basic	  concepts	  of	  sound	  clinical	  research	  methods.	  	  
	  
b.	  Selected	  tables	  or	  figures:	  
The	  following	  figure	  and	  table	  were	  prepared	  for	  the	  manuscript	  but	  was	  not	  
submitted	  due	  to	  space	  constraints.	  Some	  of	  the	  information	  was	  i cluded	  in	  the	  











Figure:	  Reasons	  treatment	  for	  tuberculosis	  was	  not	  restarted	  in	  patients	  
who	  had	  treatment	  interruption	  for	  tuberculosis	  and	  or	  antiretroviral	  
treatment	  associated	  liver	  dysfunction.	  
	  
Legend:	  	  
n:	  Number	  of	  patients	  in	  this	  category.	  
TB:	  Tuberculosis	  treatment	  















Frequency	   Percentage	  (%)	  
∗Sepsis	   66	   26.5	  
∗∗Viral	  Hepatitis	   31	   12.5	  
Alcohol	   24	   9.6	  
Gallbladder/Pancreas	  
pathology	  
24	   9.6	  
Disseminated	  TB	   23	   9.2	  
Other	   23	   9.2	  
Malignancy	   22	   8.8	  
Unknown	   12	   4.8	  
∗∗∗Cardiac	   11	   4.4	  
Cotrimoxazole	   5	   2	  
TB	  IRIS	   4	   1.6	  
Paracetomol	   3	   1.2	  
Toxins	   1	   0.4	  
	  
TB:	  Tuberculosis	  
TB	  IRIS:	  TB	  Immune	  Reconstitution	  Inflammatory	  Syndrome.	  
∗	  This	  includes	  patients	  who	  had	  bacteriologically	   roven	  sepsis	  and	  also	  
patients	  with	  a	  clinical	  picture	  of	  sepsis	  who	  were	  managed	  as	  sepsis	  by	  the	  
admitting	  team.	  	  
∗∗	  This	  includes	  acute	  hepatitis	  A	  and	  acute	  and	  chronic	  cases	  of	  hepatitis	  B.	  
∗∗∗	  Cardiomyopathy	  or	  congestive	  cardiac	  failure	  causing	  liver	  congestion	  and	  
abnormal	  liver	  function	  tests.	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
